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ABSTRACT
Type-3 long QT syndrome, which is related to type 5 voltage-gated sodium channel 
alpha subunit (SCN5A) mutation, has been identified since 1995. LQTS mutation in 
SCN5A is a gain-of-function mutation producing late sodium current, INa,L. Brugada 
mutation in SCN5A is a loss-of-function causing INa decrease. Whereas, the mechanism 
for Dilated Cardiomyopathy mutations in SCN5A is still not fully understood. 
N1325S is one of the first series of mutations identified for type-3 LQTS. Our lab 
created a mouse model for LQTS by expressing SCN5A mutation N1325S in the mouse 
hearts (TG-NS) and a matched experimental control line with overexpression of wild-
type SCN5A (TG-WT). There are some interesting findings in TG-NS mice: (i) 
Intracellular sodium (Na+) level is higher in TG-NS myocytes compared with TG-WT 
myocytes. (ii) Ca2+ handling is abnormal in TG-NS myocytes, but not in TG-WT 
myocytes. (iii) Apoptosis was also found in TG-NS mouse heart tissue, but not in TG-WT 
hearts. These results provoke the hypothesis that gain-of-function mutation N1325S in 
SCN5A leads to LQTS through abnormal cytosolic Ca2+ homeostasis. 
Another LQTS mutation in SCN5A R1193Q was identified in 2004 and the 
electrophysiological property is similar to other gain-of-function SCN5A mutations. The 
transgenic mouse model for this mutation was also established and the surface 
vi
Electrocardiogram (ECG) results indicate longer corrected QT interval also present in 
transgenic mice carrying R1193Q mutation. Besides, quinidine, an anti-arrhythmic 
medication, can cause arrhythmic symptoms such as premature ventricular contraction 
(PVC), premature atrial contraction (PAC) and atrioventricular (AV) block in R1193Q 
transgenic mice.
In order to further study the relationship between abnormal Ca2+ handling and the 
type of SCN5A mutation, either gain-of-function or loss-of-function, we have chosen
HL-1 cells, a cell line with indefinite passages in culture with all the adult cardiac 
phenotypes. The similar abnormal Ca2+ handling was also identified in HL-1 cells 
expressing N1325S mutation but not in those cells expressing wild-type SCN5A gene. 
Since we hypothesized that the abnormal Ca2+ handling is caused by INa,L created by 
gain-of-function mutation, either in HL-1 cells or in isolated TG-NS myocytes, I then use 
INa,L blocker ranolazine, a clinical trial medication for LQT patients, to specifically block 
INa,L. After the blockage of INa,L, the abnormal Ca
2+ handling was rescued in both isolated 
myocytes from TG-NS mice and HL-1 cells expressing N1325S mutation. Finally, 
several different types of SCN5A mutations related to different types of heart diseases 
were selected and the Ca2+ handling was tested in transfected HL-1 cells. 
vii
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CHAPTER I 
 
INTRODUCTION 
 
 
 
1.1 Voltage-Gated Sodium Channel Gene SCN5A 
1.1.1 The Family of Voltage-Gated Sodium Channels  
Voltage-gated sodium channels are large membrane proteins which produce 
depolarization and initiate action potentials in neurons, cardiomyocytes and skeleton 
muscle cells (Andavan and Lemmens-Gruber 2011). The sodium channels are composed 
of a large pore forming α subunit and one or several small β subunits (Abriel 2007). To 
date, there are at least twelve different α subunit isoforms and four β subunit isoforms 
that have been cloned for voltage-gated sodium channels in mammals.  
Voltage-gated sodium channel α subunit contains four homologous domains (DI to 
DIV), and each domain is composed of six transmembrane segments (S1 to S6) 
(Abriel 2007). The fourth transmembrane segment (S4) carries positively charged amino 
acids and plays an important role as a voltage sensor (Abriel and Kass 2005). The pore is 
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formed by the extracellular loop between S5 and S6 (Schroeter et al 2010). The 
site-directed mutation study in the sodium channel α subunit indicates that the activation 
of the channel is regulated by S6 (Hanlon and Wallace 2002). The fast inactivation 
involves the linker between DIII and DIV; whereas the slow inactivation is modulated by 
the conformational change of the extracellular region of the channel (Hanlon and Wallace 
2002, Ragsdale et al 1994).  
Twelve isoforms of voltage-gated sodium channel α subunits are expressed in 
different tissues (Table I). The dysfunction of sodium channels causes a variety of human 
diseases. SCN1A, SCN2A and SCN3A are mainly expressed in neurons, and the mutations 
in these three sodium channels can cause seizures and epilepsy, especially in infants 
(Baulac et al 1999, Bender et al 2012, Kearney et al 2001, Saitoh et al 2012, Wallace et al 
2001). Mutations in skeleton muscle sodium channel gene SCN4A cause hyperkalemic 
periodic paralysis and paramyotonia congenital (Meyer-Kleine et al 1994, Plassart et al 
1994). Mutations in cardiac sodium channel gene SCN5A produce persistent late sodium 
current (INa,L) and are the main cause of long-QT syndrome (LQTS), ventricular 
fibrillation (VF) and Brugada syndrome (Baroudi et al 2000, Bezzina et al 1999, Chen et 
al 2002, Deschênes et al 2000, Tian et al 2004, Tian et al 2007, Wan et al 2001, Wang et 
al 1995a, Wang et al 2004, Zhang et al 2011). In 1990, SCN6A was identified in human 
heart and uterus (George et al 1994). Later, SCN7A was assigned although the authors 
symbolized this gene as SCN6A, and the localization of SCN7A (SCN6A) was obtained 
using chromosome microdissection-PCR method (George et al 1994, Han et al 1991). 
The single nucleotide polymorphism in human SCN7A gene was found to be associated 
with essential hypertension in the Chinese population (Zhang et al 2003). SCN8A 
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Table I. Different Types of Voltage-Gated Sodium Channel Alpha Subunit 
Gene 
 
Chromosome 
Localization 
Tissue 
 
Mutation and 
Disease 
References 
 
SCN1A 2q23-q24 Brain Epilepsy and 
Dravet’s syndrome 
(Saitoh et al 2012) 
(Bender et al 2012) 
(Wallace et al 2001) 
SCN2A 2q22-q23 Brain Seizures 
 
(Kearney et al 2001) 
SCN3A 2q24-q31 
Brain and 
dorsal root 
ganglion (DRG) 
Epilepsy (Baulac et al 1999) 
SCN4A 17q23.1-q25.3 Skeletal muscle 
Paramyotonia and 
congenita 
 
(Plassart et al 1994) 
(Meyer-Kleine et al 
1994) 
SCN5A 3p21 Heart LQTS (Wang et al 1995b) 
(Bezzina et al 1999) 
SCN6A 2q21-q23 Uterus and heart Essential 
hypertension 
(George et al 1994) 
(Zhang et al 2003) 
SCN7A 2q21-q23 Glial cells and 
DRG 
N/A (Potts et al 1993) 
SCN8A 12q13 Brain, DRG and 
spinal cord 
Cerebellar atrophy, 
ataxia and mental 
retardation 
(Trudeau et al 2006) 
SCN9A 2q24 DRG, brain and 
spinal cord 
Insensitive to pain (Nilsen et al 2009) 
SCN10A 3p22-p24 DRG and heart Longer PR on ECG (Chambers et al 
2010) 
SCN11A 3p21-p24 DRG N/A (Jeong et al 2000) 
SCN12A 3p23-p21.3 
Central nerve 
system (CNS)  
and DRG 
N/A (Jeong et al 2000) 
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was found in fetal brains and the protein contains 1,980 amino acids. Interestingly, human 
SCN8A shares 98.5% sequences with the same mouse gene (Plummer et al 1998). SCN8A 
gene was first studied in mutant mice. Mutations in SCN8A in mice caused dysfunction in 
motor units such as “motor endplate disease” and mutant jointing (Burgess et al 1995, 
Kohrman et al 1996). A patient with a heterozygous two base pairs deletion mutation in 
exon 24 of SCN8A was found to have cerebellar atrophy, ataxia, and mental retardation 
(Trudeau et al 2006). Higher resistance to seizures in two mutant Scn8a mouse lines, 
Scn8a (med) and Scn8a (med-jo) suggests that mutant Scn8a can reduce the neural 
excitability (Martin et al 2007). Mutations in SCN9A were found in patients insensitive to 
pain, which is termed as “channelopathy -associated insensitivity to pain” (Nilsen et al 
2009). Genome wide association studies of SCN10A indicated that SNPs in this gene can 
lead to longer PR interval on electrocardiograms (ECG) (Chambers et al 2010). Scn11a 
was first identified in the mouse and expressed in the small sensory neurons of dorsal 
ganglia (DRG) and trigeminal ganglia (Dib-Hajj et al 1998, Dib-Hajj et al 1999). Later, 
SCN11A, which was called SCN12A, was identified in the human brain and found to be 
expressed in the central nervous system (CNS) especially in the gray matter of the 
hippocampus, cerebellum and olfactory bulb (Jeong et al 2000). 
     Although different types of sodium channels are expressed in different species and 
tissues, they are highly conserved evolutionarily. Cardiac sodium channel gene, SCN5A, 
is especially highly homologous to SCN8A and SCN9A which are primarily expressed in 
neurons (Kerr et al 2004, Plummer and Meisler 1999). SCN6A and SCN7A are actually 
orthologs in the human and mouse (George et al 1990, George et al 1994, Han et al 1991). 
SCN1A, SCN2A and SCN3A are form a gene cluster on chromosome 2q24 (Mulley et al 
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2005). SCN5A, SCN10A and SCN11A are evolutionally more closely related because they 
are tetrodotoxin-sensitive, and all located on chromosome 3p21 (Plummer and Meisler 
1999). The sequence of SCN8A is also highly similar to different domains in SCN2A, 
SCN4A and SCN5A. For example, the second domain in SCN8A is 93%, 89% and 80% 
homologous to SCN2A, SCN4A and SCN5A, respectively. However, the cytoplasmic loop 
between Domain I and Domain II in SCN8A is less identical to the other three genes 
(Plummer and Meisler 1999). 
The β subunits for voltage-gated sodium channels are glycoproteins which are not 
only the accessory part for alpha subunits, but also modulate Na+ current (INa) (Patino 
and Isom 2010). In addition, they function in cell aggregation, migration, invasion and 
neurite outgrowth when working as cell adhesion molecules (CAM) (Schroeter et al 
2010). There are at least four types of voltage-gated sodium channel β subunits referred 
to as β1-β4, which are encoded by SCN1B-SCN4B, respectively (Patino and Isom 2010).   
 
1.1.2 Type 5 Voltage-Gated Sodium Channel Nav1.5 and SCN5A Gene 
Type 5 voltage-gated sodium channel, Nav1.5, is an integrated membrane protein 
which mediates the rapid upstroke of the action potential (AP) in cardiac cells. Nav1.5 is 
the pore forming subunit of human cardiac sodium channel. The entrance of Na+ through 
Nav1.5 into a cardiac cell initiates the action potential in both ventricular and atrial 
cardiac cells (Schroeter et al 2010). Nav1.5 is encoded by the SCN5A gene which is 
located on chromosome 3p21 and is composed of 22 introns and 28 exons (George et al 
1995). Nav1.5 is a large protein containing 2,016 amino acids with an estimated 
molecular weight of 227 kDa (Wang et al 1996b). Northern blot analysis showed that this 
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gene was mainly expressed in the heart (Gellens et al 1992).  
Currently, there are several alternatively spliced Nav1.5 variants in different 
species and tissues. Nav1.5a was first observed in rat brain, and was the first cardiac 
sodium channel splice variant. Later, Nav1.5a was found in diverse tissues in rodents, but 
was not expressed in human heart (Schroeter et al 2010). Nav1.5c and Nav1.5d are two 
splice variants in human hearts. The expression of Nav1.5c is more abundant than 
Nav1.5d. In Nav1.5c, an extra glutamine residue is introduced at codon position 1077 on 
the 5’-end of exon 18. The transcriptional ratio of Nav1.5c: Nav1.5 is around 1:2, and 
there is no obvious functional differences in Nav1.5c compared with Nav1.5 (Makielski 
et al 2003). In Nav1.5d, a 120 bp fragment is deleted from exon 17, and as a result, 44 
amino acids are missing on the intracellular loop II between the second segment DII and 
the third segment DIII. Electrophysiological study has demonstrated that the channel 
kinetics is significantly changed in Nav1.5d (Camacho et al 2006, Gellens et al 1992).  
 
1.2 Cardiac Diseases and Mutations in SCN5A Gene 
In 1995, the first mutation in the SCN5A gene was identified and linked to an 
inherited cardiac arrhythmia, long QT syndrome (LQTS) (Wang et al 1995b). Since then, 
various mutations in this gene have been found and associated with numerous arrhythmic 
syndromes, such as Brugada syndrome (BrS), progressive cardiac conduction defect 
(PCCD), sick sinus node syndrome (SSS), atrial fibrillation (AF) and dilation 
cardiomyopathy (DCM) (Beggs 1997, Chen et al 1998, Lei et al 2008, Makiyama et al 
2008, Tan et al 2001). 
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1.2.1 Long QT Syndrome 
LQTS is a cardiac disorder characterized by the prolonged QT interval on the 
surface electrocardiogram (ECG), syncope and sudden death as a result of a polymorphic 
ventricular tachycardia, torsade de pointes (Wang et al 2004). Both genetic and acquired 
or environmental factors contribute to the pathogenesis of LQTS. To date, LQTS is 
known to be caused by mutations in at least thirteen genes, including the cardiac 
potassium channel genes KvLQT1 or KCNQ1 (11p15.5, LQT1) (Neyroud et al 1997, 
Splawski et al 1997a, Wang et al 1996a), HERG or KCNh2 (7q35-36, LQT2) (Curran et 
al 1995), the cardiac sodium channel gene SCN5A (3p21-24, LQT3) (Wang et al 1995a), 
the non-ion channel ankyrin-B gene encoding a protein that links ion channels to the 
cytoskeleton (4q25-27, LQT4) (Mohler et al 2003), cardiac potassium channel gene 
KCNE1 (21q22, LQT5) (Schulze-Bahr et al 2003, Splawski et al 1997b), KCNE2 (21q22, 
LQT6) (Abbott et al 1999), KCNJ2 (17q24.3, LQT7) (Tristani-Firouzi et al 2002), L-type 
Ca2+ channel CACNA1C (12p13.3, LQT8) (Navedo et al 2010), scaffolding protein 
caveolin-3 CAV3 (3p25, LQT9) (Balijepalli and Kamp 2008), the cardiac sodium channel 
gene SCN4B (11q22.3, LQT10) (Vincent 2003), A-kinase-anchoring protein-9 (AKAP9) 
(7q21.2, LQT11) (Chen et al 2007), alpha-1 syntrophin gene (SNTA1) (20q11.21, LQT12) 
(Ueda et al 2008), and potassium channel gene KCNJ5 (11q24, LQT13) (Yang et al 
2010).  
In 1995, Wang et al. reported that mutations in the cardiac sodium channel gene 
SCN5A caused type 3 LQTS. To date, there are more than 45 mutations in SCN5A that 
have been identified to be causative to LQTS. These mutations span the entire sodium 
channel from the 9th amino acid (G9V) to the last amino acid (P2006A) (Wang et al 2007). 
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The first gain-of-function mutation ΔKPQ in SCN5A produced late Na+ current (INaL) and 
was first identified in two unrelated LQTS families. ΔKPQ is a three amino acids deletion 
at position 1505-1507 locating at the intracellular loop between DIII and DIV (Wang et al 
1995b). Because of the persistent late Na+ current (INaL), which is cause by the 
fluctuation of this mutant channel between normal and non-inactivating modes, the 
cardiac action potential is prolonged, which provides a potential mechanism for this type 
of congenital LQTS (Bennett et al 1995). N1325S is another gain-of-function mutation in 
SCN5A gene causing type 3 LQTS. A transgenic mouse model which expressed mutant 
human N1325S SCN5A gene was established and showed prolonged QT interval on ECG, 
spontaneous ventricular tachyarrhythmia (VT) and ventricular fibrillation (VF) (Tian et al 
2004). 
In 2004, a missense mutation in SCN5A, R1193Q, was found in one of seven 
patients with drug-induced acquired LQTS. This mutation can destabilize inactivation 
gating and generate a persistent, non-inactivating current in both human kidney 
(HEK-293) cells and Xenopus oocytes. The biophysical defects of R1193Q are almost 
identical to two well-characterized SCN5A mutations, N1325S and R1644H 
(Wattanasirichaigoon et al 1999), which can cause type 3 LQTS. One group reported that 
SCN5A R1193Q is a polymorphism in a Chinese family that is associated with 
progressive cardiac conduction defects and long QT syndrome (Sun et al 2008). Another 
group reported that SCN5A R1193Q is a common polymorphism in general Chinese 
population. They pointed out that about 12% (11/94) of the subjects carried the R1193Q 
mutation. They analyzed clinical data from 9 of the 11 patients with the mutation. 
Although none of the carriers had Brugada syndrome, one had prolonged QTc and 
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another had borderline QTc appeared to be homozygous for R1193Q (Hwang et al 2005).   
 
1.2.2 Dilated Cardiomyopathy 
Patients with idiopathic dilated cardiomyopathy (DCM) usually have clinical 
features of an increased ventricular size and reduced ventricular systolic function (Beggs 
1997). Most mutations causing DCM are thought to have either structural defects or 
dysfunction in electrical excitation-contraction in cardiac cells. The structural defects 
caused by DCM mutations usually result in contractile filament disarray and cell death, 
and further lead to fibrosis which is the characteristics of DCM (Asahi et al 2003, Chen 
and Chien 1999, Kane et al 2005, Schmitt et al 2003).  
In 1996, SCN5A was first related to DCM after the study of a family with DCM 
associated with sinus node dysfunction, supraventricular tachyarrhythmias, conduction 
delay, and stroke (Olson and Keating 1996). Although SCN5A mutations related to DCM 
are not as common as to other cardiac diseases, the high percentage of prevalence of 
familial DCM indicates that gene defects play an important role in this cardiac disorder. 
To date, around ten mutations in SCN5A that cause DCM have been reported. However, 
the molecular mechanism by which these mutations can cause DCM is still not clear 
(Ruan et al 2009). It was also suggested that some mutations in SCN5A such as N1325S 
can cause both LQTS and DCM, and this result has already been confirmed in transgenic 
mouse model expressing N1325S mutant hSCN5A (Yong et al 2007, Zhang et al 2011).  
 
1.2.3 Brugada Syndrome 
Brugada syndrome (BrS) is a cardiac disease that is characterized by elevated 
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ST-segment in right precordial leads (V1-V3) on ECG, and it is a common form of 
idiopathic ventricular fibrillation (IVF). Patients with BrS will have increased risk in 
cardiac arrhythmias and sudden death caused by episodes of rapid polymorphic 
ventricular tachycardias (VT) or ventricular fibrillation (VF) (Brugada and Brugada 
1992). Although some patients with BrS have no symptoms on their ECG (IVF with 
normal ECG), their symptoms can be accentuated by the administration of some 
medications such as sodium channel blocker flecainide (Brugada et al 2002). 
Cardiac sodium channel SCN5A related to type 1 BrS. In 1998, the first series of 
SCN5A mutations were identified in BrS patients. T1620M is a missense mutation on the 
extracellular loop between S3 and S4 on DIV (Chen et al 1998). Nowadays, more than 90 
mutations in SCN5A are identified to be linked to BrS (Ruan et al 2009). Opposite to 
gain-of-function LQTS mutations in SCN5A, BrS mutations are loss of function 
mutations. Chen et al. stated that missense mutation T1620M locating on the extracellular 
loop between S3 and S4 on DIV exhibited a significantly faster recovery compared with 
wild-type channels. Later, the trafficking of sodium channel α subunit is also considered 
as another potential mechanism for BrS. In 2000, a missense mutation R1432G was 
reported to reduce the membrane sodium channel expression and sodium current density 
(Deschênes et al 2000). 
Besides the SCN5A gene, there are six other genes that are related to BrS. GPD1L 
(3p21-23) encoding a protein that interacts with sodium channel α subunit can cause type 
2 BrS (BrS2). CACNA1C (12p13.3) encoding calcium channel α subunit (Cav1.2) can 
cause BrS3. CACNB2 encoding calcium channel β subunit (Cavβ2) causes BrS4. SCN1B 
(19q13.1) encoding one of the sodium channel β subunit (Navβ) causes BrS5. KCNE3 
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(11q13-q14) encoding β subunit of IKs/Ito (MiRP2) causes BrS6. SCN3B (11q23.3) 
encoding type 3 β subunit of sodium channel (Navβ3) causes BrS7 (Hedley et al 2009). 
It is estimated that the prevalence of BrS is about 5:10,000 (Blangy et al 2005). 
BrS is also thought to be responsible for at least 4% of all sudden deaths and 20% of all 
sudden deaths in patients without any heart structural abnormality (Antzelevitch et al 
2007). As a result, the study of BrS mechanism is very essential. Since the BrS mutations 
in SCN5A are caused by the decreased membrane channel expression, rescuing the 
trafficking defect might be a potential treatment for BrS (Bezzina and Tan 2002, Valdivia 
et al 2002).  
 
1.2.4 Progressive Cardiac Conduction Defect (PCCD) 
Progressive cardiac conduction defect (PCCD), also known as Lev-Lenegre disease, 
is one of the most common cardiac conduction disturbances (CCD) and characterized by 
progressive alteration of cardiac conduction through the blockage of left and right His- 
Purkinje bundles and QRS complex widening (Schott et al 1999). Patients with PCCD 
ultimately develop chronic atrio-ventricular block due to the abnormal His-Purkinje 
system. As a result, pacemaker implantation is the most common treatment for patients 
with PCCD (Royer et al 2005). 
Cardiac conduction disturbance has been linked to the SCN5A gene and two other 
chromosomal locations (19q13.2-13.3 and 16q23-24) where no genes have been 
identified yet (Bezzina et al 2003, Brink et al 1995, de Meeus et al 1995, Schott et al 
1999, Tan et al 2001). In 1999, Schott first reported two mutations in two families with 
PCCD. In a large French family, a mutation of T→C substitution at position +2 of the 
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splicing donor site of intron 22 was found and expected to lead to in-frame skipping of 
exon 22, producing an impaired protein without the voltage-sensor S4 in DIII. The young 
individuals with this mutation did not show severe symptom. However, with aging and 
the increases of fibrosis, patients will develop the PCCD phenotype. In another small 
Dutch family, a deletion of a single nucleotide G at position 5280 was detected. The 
mutation results in a frameshift which produces a premature stop codon. Individuals with 
this mutation presented with a congenital conduction defect from birth, indicating that the 
effect of this premature stop codon is immediate (Schott et al 1999). Later, a missense 
mutation of G514C was identified in a 3-year old girl who experienced episodes of 
fainting during a febrile disease. Her ECG revealed typical cardiac conduction defect 
with slow conduction such as broad P waves, prolonged PR intervals and a wide QRS 
complex. The electrophysiological study in TSA201 cells expressing the G514C mutation 
showed an opposite effect on sodium current (INa) during activation and inactivation. The 
more rapidly decay of G514C channel reduces the INa accessible for cardiac impulse 
conduction. The positive shift (+7mV) of the normalized current-voltage (IV) curve 
suggested the destabilized close-state inactivation, which would increase INa (Tan et al 
2001). 
There are some PCCD mutations in SCN5A that can also cause Brugada syndrome, 
which was described as cardiac sodium channel overlap syndromes (Remme et al 2008). 
For example, a missense mutation G1406R was identified in a 45-member family. This 
mutation can either cause Brugada syndrome or isolated cardiac conduction defect 
(Kyndt et al 2001). 
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1.2.5 Sick Sinus Syndrome (SSS) 
Sick sinus syndrome (SSS), also known as sinus node dysfunction (SND), is 
characterized by variable manifestations that include inappropriate sinus bradycardia, 
sinus arrest, atrial standstill, chronotropic incompetence and tachycardia bradycardia 
syndrome. Patients with SSS always have symptoms such as dizziness or syncope 
(Benson et al 2003, Dobrzynski et al 2007) 
Besides atria and ventricles, SCN5A is also expressed in some pacemaker cells in 
sinoatrial (SA) node. Although the function of INa is still not very clear, some evidence 
suggests that Nav1.5 defects are the possible reason for some SA node dysfunction. To 
date, at least 14 mutations in SCN5A associated with SSS have been recognized (Lei et al 
2008, Ruan et al 2009). In 2003, six loss-of-function SCN5A mutations were identified in 
five SSS patients. Two of these six mutations are completely nonfunctional (G1408R and 
R1623X) and the other four are partially dysfunctional (T220I, P1298L, delF1617 and 
R1632H) (Benson et al 2003). The study of SCN5A+/- knockout mice, which develop 
symptoms such as sinus bradycardia, slowed SA conduction and SA exit block, indicates 
that the loss-of-function of Nav1.5 is the mechanism for SSS (Papadatos et al 2002). 
There are also some gain-of-function mutations in SCN5A that can cause mixed 
symptoms including SSS, LQTS, BrS and DCM. In 2003, a gain-of-function mutation 
1795insD was found to produce both persistent sodium current and a negative shift in 
inactivation. It is concluded that the effects of this persistent sodium current and the 
negative shift reduce the sinus rate, thus explaining the mechanism for QT-prolongation 
and sinus bradycardia and sinus pauses (Veldkamp et al 2003). Thus, both loss-of- 
function and gain-of-function mutations can cause the dysfunction of sinus node. 
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1.2.6 Atrial Fibrillation 
Atrial fibrillation (AF) is the most common cardiac disorder that is characterized 
by rapid and irregular activation of the atria. About 15% of all strokes are caused by AF.  
One third of patients with strokes are over 65 years of age, thus as the population ages, 
AF is responsible for the potential economic cost for the public health care system 
(Fatkin et al 2007, Matsusue et al 2012, Wang et al 2003). 
At least 11 genes are related to AF and they include both ion channel genes and 
non-ion channel genes. Mutations in both potassium channels and sodium channels can 
cause AF. The ion channel genes are KCNQ1 (α-subunit of IKs channel), KCNE2 
(β-subunit of IKs channel), KCNE5 (β-subunit of IKs channel), KCNJ2 (Kir2.1 channel), 
KCNA5 (Kv1.5 channel), SCN5A (sodium channel α-subunit), SCN1B (sodium channel 
β-subunit), SCN2B (sodium channel β-subunit), and SCN3B (Chen et al 2003, Das et al 
2009, Hong et al 2005, Makiyama et al 2008, Olson et al 2005, Olson et al 2006, Otway 
et al 2007, Ravn et al 2008, Wang et al 2010, Watanabe et al 2009, Yang et al 2004). The 
non-ion channel genes are NUP155 (nucleoporin), GJA5 (connexin-40) and NPPA (atrial 
natriuretic peptide (mANP)) (Gollob et al 2006, Hodgson-Zingman et al 2008, Oberti et 
al 2004, Zhang et al 2008). 
In 2008, a SCN5A mutation M1875T was found in a Japanese family with only AF. 
This family has no symptoms of structural heart disease or ventricular arrhythmias. The 
electrophysiological study showed that M1875T is a gain-of-function mutation without 
producing persistent inward Na+ currents. The characteristic of this mutation is obviously 
different from the LQT-type gain-of-function mutations which produce persistent late 
sodium current (Makiyama et al 2008).   
15 
 
1.2.7 Overlapping Syndromes 
The effects of mutations in SCN5A are usually complicated. As a result, patients 
carrying certain mutations will display not only one type of symptom, but a mixed 
syndromes. Numerous SCN5A mutations lead to mixed phenotypes, known as a 
overlapping syndrome of cardiac sodium channelopathy (Remme et al 2008). 
In 1999, Bezzina et al. first revealed that a single SCN5A mutation could cause 
multiple cardiac disorders within the same family. They found out that the family 
carrying 1795insD mutation in SCN5A presenting ECG features of sinus node 
dysfunction, bradycardia, BrS and LQTS (Bezzina et al 1999). Later, another deletion 
mutation ΔK1500 was reported to cause LQTS, BrS and conduction disease (Grant et al 
2002). To date, more than 30 mutations in SCN5A can cause different combination of 
cardiac diseases. Most of these combinations are cardiac conduction dysfunction (CCD) 
and Brugada syndrome (BrS) (Table II). 
 
1.3 Cardiovascular System 
1.3.1 The Structure of the Cardiovascular System 
The cardiovascular system is composed of the heart and blood vessels, which 
supply oxygen and nutrition throughout the body. The heart is a muscular organ that 
propels blood while contracting. There are four chambers in the human heart: left and 
right atria and ventricles. There are two types of blood circulation systems in the human 
body. Pulmonary circulation carries oxygen-deprived blood from the right ventricle 
through the pulmonary artery to lungs, and then returns it back to the left atrium with 
oxygenated blood through the pulmonary vein. Systematic circulation carries oxygenated  
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Table II. Overlapping Syndrome of Cardiac Sodium Channelpathy 
SCN5A 
Mutation 
Clinical Phenotype 
References 
LQTS BrS CCD SSS Other 
E161K  + + +  (Smits et al 2005) 
T187I  +  +  (Makiyama et al 2005) 
P336L  + +   (Cordeiro et al 2006) 
D365N  + +   (Makiyama et al 2005) 
R367H  + +   (Takehara et al 2004) 
R376H  + +   (Rossenbacker et al 2004) 
N406S  + +   (Itoh et al 2005) 
G752R  + +   (Potet et al 2003) 
F861fs951X  + +   (Schulze-Bahr et al 2003) 
E867X  + +   (Schulze-Bahr et al 2003) 
D1114N + +    (Splawski et al 2000) 
W1191X  + +   (Shin et al 2007) 
E1225K  + + +  (Schulze-Bahr et al 2003) 
D1275N   +  AF/DCM (McNair et al 2004) 
G1319V  + +   (Casini et al 2007) 
P1332L +  +   (Ruan et al 2007) 
I1350T  + +   (Juang et al 2003) 
G1406R  + +   (Kyndt et al 2001) 
G1408R   + +  (Kapplinger et al 2010) 
ΔK1479  + + +  (Schulze-Bahr et al 2003) 
ΔK1500 + + +   (Grant et al 2002) 
ΔKPQ +  +   (Wang et al 1995b) 
ΔF1617 + +  +  (Chen et al 2005) 
R1623X   + +  (Makiyama et al 2005) 
R1632H   + +  (Benson et al 2003) 
I1660V  + +   (Cordeiro et al 2006) 
S1710L  + +   (Akai et al 2000) 
V1763M +  +   (Chang et al 2004) 
M1766L +  +   (Valdivia et al 2002) 
V1777M +  +   (Lupoglazoff et al 2002) 
1795insD + + +   (Bezzina et al 1999) 
S1812X  + +   (Schulze-Bahr et al 2003) 
P2005A +  +   (Shim et al 2005) 
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blood from the left ventricle through the aorta to the rest of the body, and then returns it 
back to the right atria with oxygen-deprived blood (Luca et al 2009). The cardiac muscle 
contraction is caused by the electrical signal turned by excitation-contraction coupling in 
cardiac muscle cells. 
 
1.3.2 Electrical Conduction in the Heart and Electrocardiogram (ECG) 
The electrical signal arisen by cardiac action potentials starts at the sinoatrial 
node (SAN), which is located in the upper side of the right atrium. SAN sends the 
impulse to the right atrium, to the left atrium through Bachmann’s bundle, and then to the 
atrioventricle (AV) node. The electrical signal of left and right atria generates the P wave 
on the electrocardiogram (ECG). The AV node plays an important role in delaying the 
ventricle contraction. Without the delay of AV node, ventricles and atria would beat at the 
same time. Two branches of His bundles in AV node, left and right branches, activate two 
ventricles, respectively and generate the PR segment on the ECG. The His bundles then 
branch to produce a bunch of Purkinje fibers, which spread the electrical impulse in 
ventricles, and form the QRS complex on the ECG (Klabunde 2012). 
 
1.4 HL-1 Atrial Cells 
1.4.1 Development of HL-1 Cardiomyocytes 
In 1998, William C Claycomb successfully derived a cardiac muscle cell line, 
named HL-1, from the AT-1 mouse atrial cardiomyocyte tumor lineage. HL-1 cells can be 
passed infinitely, and still maintain the phenotype of cardiomyocytes. With specific 
culture media, HL-1 cells can be cultured beyond 30 passages and still remain beating 
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and contain no other cell types. With immunochemistry tests, HL-1 cells were confirmed 
to have perinuclear ANF-containing granules, cardiac-specific myosin and muscle- 
specific desmin intermediate filaments. These immunochemistry observations confirmed 
that HL-1 cells possess cardiac morphological properties. The gene expression analysis 
using RT-PCR (reverse transcription PCR) identified the presence of adult isoform of 
myosin (α-MHC) and contraction proteins such as α-cardiac actin, ANF and connexin43 
(CX43). The gene expression results revealed that HL-1 cells retained biochemical 
characteristics of cardiac cells. Finally, Claycomb reported that HL-1 cells showed 
spontaneous action potentials and repolarizing K+ currents using whole cell patch-clamp 
technique (Claycomb et al 1998).  
 
1.4.2 Studies of Cardiac Muscle Cell Structure and Function Using HL-1 
Cardiomyocytes 
Before the development of HL-1 cardiomyocytes, isolated embryonic or neonatal 
rat and mouse cardiomyocytes were most widely used for cardiac studies. However, 
embryonic or neonatal cardiomyocytes lack the adult myocyte phenotypes. Some labs are 
also using isolated adult cardiomyocytes, but these adult cardiomyocytes cannot be 
cultured, and they are difficult to be transfected. The technique of adult cardiomyocytes 
isolation also highly depends on the quality of enzymes. The invention of HL-1 cells, the 
only cardiac cell line that can be continuously divided and still maintain the adult cardiac 
phenotypes in culture, provides a model for the study of cardiac diseases (White et al 
2004). 
HL-1 cardiomyocytes were first used to study the change of gene expression in 
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cardiac cells under pathophysiological stress such as hypoxia, hyperglycemia, and 
hyperinsulinemia (Collier et al 2002, Nguyen and Claycomb 1999). HL-1 cells were also 
used to study cellular signaling pathways and different types of receptors in cardio- 
myocytes.  
 
1.5 Regulation of Nav1.5 Function in Cardiac Cells 
1.5.1 Ankyrin Proteins 
There are three ankyrin proteins encoded by ANK1, ANK2 and ANK3 genes. 
Ankyrin-B (encoded by ANK2) and ankyrin-G (encoded by ANK3) are expressed in the 
heart (Cunha and Mohler 2006). Although in ankyrin-B knockout mice, late opening of 
Nav1.5 was observed in isolated neonatal myocytes, there is no evidence showing that 
ankyrin-B directly interacts with Nav1.5 (Chauhan et al 2000). However, ankyrin-G was 
found to directly interact with Nav1.5 on the loop between DII and DIII on a 9 amino 
acid conserved motif (Lemaillet et al 2003). In 2004, a BrS mutation in Nav1.5, E1053K, 
was reported by Mohler et al. This mutation is in the ankyrin-G binding motif and 
disrupts the interaction between ankyrin-G and Nav1.5. As a result, Nav1.5 cannot be 
transferred to plasma membrane, and tracked in the cytoplasm. These findings suggest 
that ankyrin-G functions as a helper for Nav1.5 trafficking and sorting (Mohler et al 
2004). 
 
1.5.2 Caveolin-3 
The cell membrane is composed of lipids and proteins. According to Singer and 
Nicholson’s fluid-mosaic model about the cell membrane, proteins can float in the 
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phospholipid bilayers freely (Brown and London 1998). The less fluid liquid-order phase 
(Lo) is created by phospholipids with longer saturated acyl chains of the fatty acids and 
cholesterol pack, and the more fluid liquid-disorder phase (Ld) is composed of phospho- 
glycerolipids with polyunsaturated fatty acids (Binder et al 2003). Lo microdomains, 
called lipid rafts, function as signal transduction and protein-protein interactions to adapt 
the environmental changes. Caveolae, the best characterized lipid raft, is small embolic 
membrane structures (Palade 1953). Caveolae is rich in cholesterol and sphingolipids 
with cholesterol-binding proteins called caveolin. Caveolins are small proteins with 
several isoforms. Among these isoforms, caveolin-3 is highly expressed in myocytes, and 
it is encoded by CAV3 gene (Song et al 1996, Tang et al 1996, Williams and Lisanti 2004). 
The co-immunoprecipitation and immunochemistry studies for caveolin-3 indicate that 
Nav1.5 interacts and co-localizes with caveolin-3 (Yarbrough et al 2002).  
 
1.5.3 Nav 1.5 β-Subunits 
Sodium channels are composed of one pore forming α subunit and one or several 
auxiliary β subunits that regulate the channel function (Meadows and Isom 2005). There 
are four genes encoding human sodium channel β subunits: β1 (SCN1B) (Isom et al 1992), 
β2 (SCN2B) (Isom et al 1995), β3 (SCN3B) (Morgan et al 2000), and β4 (SCN4B) (Maier 
et al 2003). These four β subunits have different regulatory functions for Nav1.5. 
Coexpression of β1 and Nav1.5 results in a current density increase (Qu et al 1995). 
Coexpression of β3 and Nav1.5 increases current density, depolarizes shifts in the 
voltage-dependence of inactivation, and increases the rate of recovery from inactivation 
(Fahmi et al 2001). However, anther group claimed that β3 causes hyperpolarizing shifts 
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in inactivation and slows the recovery form inactivation (Ko et al 2005). As a result, the 
study about the effect of β3 on Nav1.5 is controversial. Coexpression of β2 and β4 with 
Nav1.5 has no obvious effect on the current (Dhar Malhotra et al 2001, Yu et al 2003), 
though one group found that when expressed in HEK 293 cells, a mutation (L179F) in 
SCN4B increases the late sodium current, which is similar to gain-of-function mutations 
in SCN5A such as ΔKPQ (Medeiros-Domingo et al 2007).  
It appears that the effect of β subunits on Nav1.5 is inconclusive and controversial 
due to the possibility that the interaction between a β subunit and Nav1.5 α subunit is 
complicated and that different groups used in different cell types. β1 and β2 subunits are 
associated with ankyrin, another important Nav1.5 regulation protein discussed above. 
The localization of β1-ankyrin complex is controlled by the phosphorylation of the 
tyrosine on β1 carboxyl-terminus (Y181) (Malhotra et al 2002). Using a phosphorylated 
antibody, tyrosine phosphorylated β1-ankyrin complex was found to colocalize with 
Nav1.5 at the intercalated disk (Malhotra et al 2004).   
 
1.5.4 Protein Kinase A (PKA) 
In cardiac cells, the β-adrenergic receptor activates a GTP-binding protein (Gs). 
This GTP-binding protein then stimulates adenylyl cyclase and leads to the increase of 
intracellular cAMP, which will activate PKA (Li et al 2000). It is found that PKA 
activation can increase INa by at least 30% in normal canine cardiomyocytes, but can only 
increase INa by 17% in the cells at infracted zone. Since it was hypothesized that PKA 
activator could either increase the current by direct phosphorylation of the α subunit or 
facilitate the channel trafficking from ER to plasma membrane (Frohnwieser et al 1997, 
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Murphy et al 1996, Zhou et al 2000), cholorquine, an inhibitor of cell trafficking, was 
used to distinguish the two hypotheses. After the administration of cholorquine, the peak 
INa did not change much in infracted cells, but increased only 10% in the noninfracted 
cells (Baba et al 2004). This result indicates that PKA activator increases INa by pushing 
more sodium channels to plasma membranes. Later, another group used GFP tagged 
Nav1.5 to provide direct evidence that PKA helped the trafficking of cardiac sodium 
channels. They demonstrated that in the stable cell line expressing GFP- Nav1.5, more 
sodium channels localized onto the membrane, and the peak INa increased after applying 
PKA activators (Hallaq et al 2006).  
 
1.5.5 Tyrosine Phosphorylation of Nav1.5 
Many ion channels are the targets for protein phosphorylation and 
dephosphorylation, which then alter the electrophysiological properties and activities of 
the excitable cells. It was proved that voltage-gated sodium channel α subunit can be 
negatively regulated by PKA phosphorylation on Ser573 located on the intracellular loop 
between DI and DII (Cantrell et al 1997). Sodium channel α subunit can also be regulated 
by PKC so that the peak current was reduced by a negative shift of steady-state 
inactivation in the hyperpolarized direction (Qu et al 1994).  
The study of tyrosine phosphorylation is more recent. One group suggested that 
cardiac sodium channels can be phosphorylated by Src family tyrosine kinases. Using the 
anti-phosphotyrosine antibody, the immunoprecipitated Nav1.5 was increased in cells 
expressing constitutively activated Src family tyrosine kinase Fyn. The phosphorylated 
residue (Y1495) in Nav1.5 was also found (Ahern et al 2005). Another group studied the 
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effect of tyrosine kinases on INa in guinea pig ventricular myocytes. In their study, INa 
increased when being treated with epidermal growth factor (EGF). The increased INa can 
be inhibited by epidermal growth factor receptor (EGFR) kinase inhibitor tyrphostin 
AG556 and enhanced by orthovanadate (a protein kinase phosphatase inhibitor) (Liu et al 
2007). Jespersen T. et al found that Nav1.5 interacts with protein tyrosine phosphatase 
PTPH1 and concluded that tyrosine phosphorylation destabilizes the inactivated state of 
Nav1.5 (Jespersen et al 2006). 
 
1.5.6 Glycerol-3-Phosphate Dehydrogenase Like Protein (GPD1-L) 
In 2002, a locus on chromosome 3 was described in a large family with BrS, but no 
mutation was found in SCN5A gene, which is located nearby (Weiss et al 2002). Later, a 
missense mutation in GPD1-L, the glycerol-3-phosphate dehydrogenase like protein, was 
found in this BrS family. As a result, it brought attentions about the interaction between 
GPD1-L and SCN5A which is an important BrS gene. When co-expressed with SCN5A in 
HEK293 cells, this BrS mutation in GPD1-L can reduce INa (London et al 2007). Three 
more mutations in GPD1-L were found in some patients died of sudden infant death 
syndrome (SIDS). The expression of these mutant GPD1-L variants in mouse neonatal 
cardiomyocytes decreases INa (Van Norstrand et al 2007). 
 
1.5.7 Calmodulin (CaM) 
Calmodulin (CaM) is a Ca2+ sensor protein and can undergo a Ca2+-induced 
conformational change. This small ubiquitous intracellular Ca2+-binding protein with 
only 147 amino acids participates in numerous signaling pathways and cellular processes 
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such as growth, proliferation and movement (Chin and Means 2000). During the cardiac 
excitation-contraction coupling, Ca2+ handling =is crucial for many physiological events 
(Saimi and Kung 2002). When interacting with other proteins, CaM usually binds to the 
isoleucine-glutamine (IQ) CaM binding motif on these proteins (Herzog et al 2003). In 
2002, Tan HL and co-workers found the IQ motif on the C-terminus of Nav1.5. The 
binding of CaM significantly potentiates slow inactivation (Tan et al 2002). It is also 
found that Ca2+ concentrations can modulate Na+ channel through CaM (Kim et al 2004), 
but recent studies suggest that this modulation is caused by the Ca2+ binding motif on the 
proximal part of Nav1.5 C-terminus (Shah et al 2006, Wingo et al 2004). 
 
1.5.8 Ca2+/Calmodulin-Dependent Protein Kinase II (CaMKII) 
CaMKII, a serine/threonine protein kinase, is activated by intracellular [Ca2+] 
changes. There are four CaMKII isoforms: α, β, δ, and γ, and each isoform is encoded by 
a specific gene. All the CaMKII isoforms have similar core structures including a 
regulatory domain, an N-terminal catalytic domain, and a C-terminal association domain 
(Braun and Schulman 1995). CaMKIIδ is predominantly expressed in the heart 
(Couchonnal and Anderson 2008). Using immunoprecipitation and immunostaining, it 
has been confirmed that CaMKIIδc interacts and co-localizes with Nav1.5 in mouse 
myocytes. By overexpressing CaMKIIδc in rabbit myocytes, Stefan Wagner et al. 
successfully proved that CaMKIIδc was able to enhance the steady-state inactivation of 
INa (Wagner et al 2006). The mice overexpressing CaMKIIδc in the hearts developed 
chronic heart failure and episodes of ventricular tachycardia. Not only does CaMKII 
interact with Nav1.5 and regulate INa in the myocytes, it is also an important protein 
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linking Ca2+ and Na+ in the cardiac cells. As a result, CaMKII is a potential drug target 
for arrhythmia treatment (Abriel et al 2000). 
 
1.5.9 MOG1  
MOG1 was first identified as a multi-copy suppressor of the yeast nuclear transport 
factor GSP1 or scRan. It is a small protein encoded by RANGRF gene with molecular 
weight of 29 kDa (Marfatia et al 2001, Oki and Nishimoto 1998)). Yeast two-hybrid and 
in vitro binding experiments indicate that MOG1 binds to the GTP-binding nuclear 
protein Ran. As a result, MOG1 is thought to regulate nuclear protein trafficking 
(Marfatia et al 2001). In 2008, Ling Wu et al. found that MOG1 interacts with Nav1.5 on 
the intracellular loop between DII and DIII by a yeast two hybrid screen followed by 
GST-pull down assays and co-immunoprecipitation. In HEK293 cells stably expressing 
Nav1.5, transfection of MOG1 can increase the Nav1.5-mediated peak current without 
affecting any kinetic changes of sodium channel. These results suggested that MOG1 is a 
helper protein for Nav1.5 transporting to the plasma membrane (Wu et al 2008). 
 
1.5.10 Fibroblast Growth Factor Homologous Factor 1B (FHF1B or FGF12-1b) 
Fibroblast growth factor (FGF) family is one of the largest families of polypeptide 
growth factors functioning in both the adult and the embryos (Olsen et al 2003). One of 
the family members, FGF12-1b (also known as FHF1B (fibroblast growth factor 
homologous factor 1B)), is expressed in the heart (Abriel et al 2000). It is reported that 
FGF12-1b interacted with Nav1.5 at intracellular C-terminus motif of amino acid 
1773-1832 (Goetz et al 2009, Liu et al 2003). Several LQTS and BrS mutations such as 
26 
 
E1784K, D1790G, and Y1795H and Y1795C in SCN5A are located in this FGF12-1b 
binding motif. In HEK293 cells co-expressing FGF12-1b and Nav1.5, the steady-state 
inactivation curve shifted toward hyperpolarized value without any change in the peak 
current density. However, FGF12-1b does not modulate or interact with D1790G mutant 
Nav1.5 (Liu et al 2003). 
 
1.5.11 14-3-3η Protein 
14-3-3 proteins are highly conserved proteins with a molecular weight of 28-33 
kDa in all eukaryotic organisms (Aitken 2006). Severn family members of 14-3-3 
proteins are found in mammals – β, γ, ε, σ, ζ, τ and η (Morrison 2009). The yeast 
two-hybrid and co-immunoprecipitation experiments indicate that 14-3-3η interacts with 
the intracellular N-terminus of Nav1.5. The immunostaining in COS-7 cells expressing 
human Nav1.5 and 14-3-3η demonstrated that these two proteins were co-localized at the 
intercalated disk of myocytes. The same result was confirmed in isolated rabbit 
cardiomyocytes. Co-expression of 14-3-3 did not change the peak sodium current in 
COS-7 cells, but shifted the inactivation curve towards negative potential and delayed the 
recovery from inactivation. This result indicates that 14-3-3 does not regulate the 
trafficking of Nav1.5 but modified its kinetics (Allouis et al 2006).  
 
1.5.12 Ubiquitin-Protein Ligases of the Nedd4/Nedd4-Like Family 
Intracellular and extracellular protein degradation processes are different. During 
extracellular degradation, the extracellular proteins are engulfed by vesicles and then 
fused with primary lysosomes (Glickman and Ciechanover 2002). However, during the 
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intracellular protein degradation, it undergoes the two-steps ubiquitin-proteasome 
proteolytic pathway: 1) tagging of the proteins with ubiquitin molecules, and 2) 
degradation of the tagged proteins by the 26S proteasome complexes. Ubiquitin can be 
recycled during this process (Glickman and Ciechanover 2002). Besides protein 
degradation, ubiquitin can also regulate protein trafficking to cell membranes (Staub and 
Rotin 2006).  
Ubiquitin is a small protein with only 76 amino acid residues (Hershko and 
Ciechanover 1998). The Nedd4/Nedd4-like family of E3 ubiquitin-protein ligase contains 
a 40-residue domain that binds to various proteins with their PY motifs (Rotin and Kumar 
2009). Almost all voltage-gated sodium channels have this PY motif on their intracellular 
C-terminus except for Nav1.4, Nav1.9, and Nax (Fotia et al 2004). It is observed that INa 
was reduced by Nedd4-2 mediated ubiquitylation in Xenopus oocytes (Abriel et al 2000). 
Since the total Nav1.5 protein did not decrease in the presence of Nedd4-2, it is unlikely 
that the reduction of INa was Nav1.5 protein degradation by Nedd4-2. Instead, Nav1.5 
proteins are trapped inside the cells by Nedd4-2 rather than pushed to the membrane 
(Rougier et al 2005). 
 
1.6 Anti-Arrhythmic Medications and Their Side Effects. 
1.6.1 Quinidine 
Quinidine, a class I anti-arrhythmia drug, used to be one of the most frequently 
prescribed anti-arrhythmic drugs, but has side effects that may lead to arrhythmias (Grace 
and Camm 1998). The pharmacokinetic study of quinidine revealed that the half life of 
quinidine in humans ranges between 3 and 19 hours (Grace and Camm 1998). In cardiac 
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cells, quinidine can block fast inward sodium currents and various potassium channels 
(Balser et al 1991, Wwidmann 1955). The anti-arrhythmic effect of quinidine was 
thought to be caused by the inhibition of the repolarizing delayed rectifier current, which 
is composed of three components including slow, rapid and ultrarapid currents (Deal et al 
1996, Wang et al 1995c). Quinidine functions to inhibit the rapidly activating component 
(Carmeliet 1993, Woosley et al 1993). 
Initially, quinidine was used for patients with atrial fibrillation (AF), and then was 
widely used as anti-arrhythmic medication (Brodsky et al 1996). However, it was later 
found that the application of quinidine has a potential risk of causing syncope and sudden 
death, which are due to ventricular tachycardia (VT) (Selzer and Wray 1964). The 
arrhythmia induced by quinidine treatment often happened right after treatment was 
started, and about 1.5%-8% of patients developed torsade de pointes (TdP) with quinidine 
treatment especially in patients with AF (Roden et al 1986, Roden 1994). Patients who 
developed TdP when treated with quinidine usually have abnormally longer corrected QT 
interval on ECG (Roden et al 1986).  
 
1.6.2 Mexiletine 
Mexiletine is another class I antiarrhythmic drug which plays an important role in 
treating cardiac arrhythmias (Sheets et al 2010). Voltage-gated sodium channels possess 
different types of inactivation, including fast, slow and ultra-slow (Goldin 2008). The 
slow inactivating component current INa,P  is only 1% of the peak current INa, T and 
considered the main target for antiarrhythmic drugs such as mexiletine and ranolazine 
(Saint 2008). 
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Like other antiarrhythmic drugs, mexiletine can also promote arrhythmias 
(Brugada and Wellens 1988). However, a series of test of different antiarrhythmic drugs 
indicated that mexiletine might have the lowest risk of proarrhythmic action (Dhein et al 
1993).  
 
1.6.3 Ranolazine 
Ranolazine is an investigative anti-arrhythmia drug in phase III trials, and believed 
to block four different voltage-gate sodium channels including Nav1.1, Nav1.5, Nav1.7 
and Nav1.8 (Antzelevitch et al 2011). The effect of ranolazine in treating arrhythmias is 
the blockage of multiple channels such as late sodium current (INa,L), the late rectifying 
potassium channel, and the late L-type calcium channel. It is known that the inhibition of 
potassium channel will prolong the action potential duration (APD) and the inhibition of 
sodium channel and calcium channel will shorten the APD. The opposite effects of 
ranolazine on APD explain the modest prolongation effect on QTc in patients (Reddy et 
al 2010). Similar to quinidine, the QTc increase effect of ranolazine might bring the 
problem of developing drug-induced TdP. However, no such symptoms were observed 
during ranolazine clinical trials (Reddy et al 2010). It is reported that only less than 2% 
patients experienced the common side effects of ranolazine such as dizziness, nausea, 
constipation and headache (Chaitman et al 2004, Morrow et al 2007, Stone et al 2006).   
Mutagenesis study demonstrated that mutation F1760A in Nav1.5 significantly 
reduced the blockage effect of ranolazine on both peak and sustained Na+ current. It is 
indicated that ranolazine interacted with the previously defined local anesthetic (LA) 
receptor binding site on Nav1.5 (Fredj et al 2006). One group reported that ranolazine 
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blocked Nav1.5 through modulating the mechanosensitivity of this voltage-gate channel 
by partitioning the lipid bilayer of the membrane (Beyder et al 2012). Nav1.5 is 
mechanosensitve in both cardiac myocytes and a heterologous system such as transfected 
HEK cells, and is regulated by cytoskeleton and membrane lipid bilayer elasticity 
(Lundbaek et al 2004, Undrovinas et al 1995). The interruption of lipid bilayer inhibits 
the mechanosensitivity of Nav1.5 (Beyder et al 2012). 
 
1.6.4 Other Anti-Arrhythmic Drugs 
Although newer drugs were developed and showed more clinically effective for 
cardiac arrhythmia treatment, the side effect of these newer drugs brought concerns to 
physicians. These newer drugs include flecainide, encainide, and moricizine, and were 
found to cause ventricular premature beats after myocardial infarction and lead to 
mortality in patients (Echt et al 1991). The lethal side effects brought attention to 
scientists, and the study of how to reduce the side effects of the medications could be 
more important than alleviating the symptoms.  
 
1.7 Cardiac Excitation-Contraction Coupling (ECC) and Ca2+ Handling in Cardiac 
Cells 
1.7.1 The Importance of Ca2+ in Cardiomyocytes 
Cardiac excitation-contraction coupling is the process of the contraction of the 
cardiac cells to the contraction of the heart, which propels out blood to the body. 
Throughout this process, Ca2+ ion plays an important role in translating the cell electrical 
excitation signal to the contraction of myofilaments. Thus, the mishandling of Ca2+ may 
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cause cardiac dysfunction such as arrhythmias (Bers 2002). In the past several decades, 
alterations in cytosolic Ca2+ homeostasis were considered as the main mechanism for cell 
death. Ca2+ paradox is the hypercontracture and death of cardiomyocytes caused by Ca2+ 
restoration after a perfusion of Ca2+-free buffer (Piper 2000). Hypercontraction can cause 
cardiac cell death, and the inhibition of hypercontraction using 2,3-butanedione 
monoxime (BDM) during reperfusion can prevent the further damage of the cell tissues 
(Garcia-Dorado et al 1992). 
Ca2+ is a crucial element in all kinds of organisms, and plays an important role in 
numerous biological functions. It is known that the intracellular free Ca2+ concentration 
(~10-7 M) is much lower than the extracellular Ca2+. This high Ca2+ gradient provides 
abundant Ca2+ available to be imported into cells, where these Ca2+ ions can function as 
second messengers (Chin and Means 2000).  
 
1.7.2 The Process of Excitation-Contraction Coupling (ECC) 
In order to initiate the cardiac ECC, Na+ ions need to enter the cardiac cells through 
voltage. Then, a relatively small amount of Ca2+ enters the cell through depolarization- 
activated Ca2+ channels such as L-type Ca2+ channel (Figure 1). This small amount of 
Ca2+ then open RYR2 on sarcoplasmic reticulum (SR) membrane and release the Ca2+ 
storage in SR. This process is called Ca2+ induced Ca2+ release (CICR). The rapid 
intracellular Ca2+ increase allows the binding of Ca2+ to the protein troponin complex 
(TN-C) which attaches to sarcomere, the myofilament repeat subunit in striated muscle 
(Knollmann and Roden 2008). The binding of Ca2+ to TN-C induces a conformational 
change and exposes the myosin binding sites (thick filament) on actin (thin filament).  
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Figure 1. Schematic Diagram of Cardiac Excitation-Contraction Coupling (ECC) Events 
in Ventricular Myocytes. In order to initiate ECCs, K+ ions enter into the cell from a 
neighboring cell through connexin channels and open the voltage gated Na+ channels, 
which leads to the depolarization of the membrane. The depolarization of the membrane 
causes Na+ channel inactivation and opens both K+ channels and L-type Ca2+ channels. 
The entry of Ca2+ ions releases sarcoplasmic reticulum (SR) Ca2+ into cytosol. This rapid 
increase of cytosolic Ca2+ ions will bind to the troponin complex and activate the 
myofilament contraction. During the repolarization process, the cell will remove 
cytosolic Ca2+ either through Na+/Ca2+ exchanger (NCX) or Ca2+-uptake pumps on SR. 
The cytosolic Na+ is excluded through the Na+/K+ pump. 
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Following the conformational change leads to movement and binding between myosin 
and actin and results in the muscle contraction. This is the physiological process that how 
the electrical stimulus is translated to the striated muscle contraction (Sandow 1952). 
 
1.7.3 Cardiac Ion Channels and Cardiac Action Potential 
In a cardiac cell, an action potential (AP) refers to the rapid rise and fall of a cell 
electrical membrane potential. The cardiac action potential is electrical activity in the 
heart and is crucial for the electrical conduction in the heart (Grant 2009). The AP 
contains five phases (Figure 2), including the upstroke (0), early repolarization (1), 
plateau (2), final repolarization (3) and resting phases (4), all of which are generated by 
different selective ion channels on the membranes (Table III) (Grant 2009).  
 
1.7.4 The Cellular Relaxation and the Removal of Cytosolic Ca2+ 
In order to exclude the increased Ca2+ in cytosol, Ca2+ ions have to be transported 
out of the cell or be pumped back to SR in order to allow cell relaxation (Bers 2002). A 
SR Ca2+-ATPase called SERCA on SR membrane pumps the rapidly increased Ca2+ back 
into SR. Na+/Ca2+ exchanger (NCX) allows three Na+ enter the cell and exclude one Ca2+ 
outside the cell.  This is the main path for Ca2+ transport out of the cytosol (Pogwizd et 
al 2001). There are two more pathways to exclude extra Ca2+: sarcolemmal Ca2+-ATPase 
and mitochondrial Ca2+ uniporter (Bassani et al 1994). 
 
1.7.5 Dysfunction of Na+/Ca2+ Exchanger Causes Ca2+ Overload and Arrhythmias 
Na+/Ca2+ exchanger (NCX), an important protein linking Ca2+ and Na+ in the cell, 
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Figure 2. A Schematic Diagram Showing that Different Ionic Currents Contribute to 
Different Phases of a Cardiac Action Potential. During phase 0, the rapid inward sodium 
current INa initiates the upstroke of the action potential through Nav1.5 channels. This 
phase is followed by the inactivation of Na+ channels and the efflux of K+ ions. Next, the 
action potential enters into a plateau phase (2) in which the inward movement of Na+ and 
Ca2+ and the outward movement of K+ are balanced. The final repolarization phase 3 is 
achieved by fast delayed rectifier, which is an outward K+ current.  
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Table III. Ionic Currents and Different Phases of AP 
Currents Channel Gene AP Phase Description 
INa SCN5A 0 &2 Sodium current 
Ito 
KCND2/3, KCNA4 
KCNA7, KCNC4 
1 Transient outward current 
IKur KCN5A, KCNC1 1 Ultrarapid delayed rectifier 
ICa,L CACNA1C 2 L-type calcium current 
INCX NCX1.1 2 Influx of Na
+ through NCX 
IKr KCNH2 3 Fast delayed rectifier 
IKs KCNQ1 3 Slow delayed rectifier 
IK1 KCNJ2/12 4 Inward rectifier 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
is a bi-directional membrane ion transporter (Jeffs et al 2007). There are two modes in 
NCX: the forward mode and reverse mode. The direction of the mode of NCX is 
determined mainly by intracellular and extracellular concentrations of Na+ and 
Ca2+ (Blaustein and Lederer 1999). Under normal physiological conditions, NCX 
functions in the forward mode, which allows three Na+ ions enter the cell and one Ca2+ 
moves out of the cell (McNaughton 1991). However, during the ischemia condition, the 
shortage of ATPs decreases the ability of Na+ extrusion through the energy-dependent 
Na+/K+-ATPase, which further causes the intracellular Na+ overload (Murphy et al 1991). 
Another study also showed that the inhibition of Na+/K+-ATPase may cause elevation of 
[Na+] and SR Ca2+ overload (Sedej et al 2010). It is believed that the elevated [Na+] leads 
to the reduced function of the NCX forward mode, which means that less Ca2+ ions are 
excluded through NCX and therefore leads to SR Ca2+ overload (Sedej et al 2010). SR 
Ca2+ overload has been experimentally proven to be the main cause for delayed 
afterdepolarizations (DADs) (Lederer and Tsien 1976, Marban et al 1986). DAD is the 
depolarization occurring after depolarization and related to initiation arrhythmias (Fink et 
al 2011, Pogwizd and Bers 2004). 
 
1.7.6 Intracellular Ca2+ Transient and the Development of Ca2+ Transient 
Measurement 
Ca2+, an important signaling ion in the cytosol, regulates the cardiac cell 
contraction through binding to the Ca2+ binding protein troponin complex on 
myofilaments. The affinity between Ca2+ ions and Ca2+ binding proteins depends on the 
dynamic intracellular Ca2+ concentration, referred to as Ca2+ transient (Wier 1990). 
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Therefore, Ca2+ transient in striated muscle cells has provoked great interests of many 
scientists. 
During the development of methods for the measurement of Ca2+ transient, fura-2 
was proven to be an efficient Ca2+ fluorescent indicator in individual ventricular cells 
(Grynkiewicz et al 1985). Fura-2-acetoxymethyl ester (Fura-2/AM) is a membrane 
permeable Ca2+ indicator. Once entering into the cells, the cellular esterases will remove 
the acetoxymethyl groups on Fura-2/AM, and then Fura-2, the real working Ca2+ 
fluorescent indicator, is generated. The ratio of fluorescence at 340 nm and 380 nm 
(340/380) is proportional to the intracellular Ca2+ concentration (Grynkiewicz et al 1985). 
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CHAPTER II. 
 
CARDIAC EXPRESSION OF SCN5A SNP R1193Q IN TRANSGENIC MICE 
PROLONGS QT INTERVAL 
 
 
 
2.1 Abstract 
     Type 3 LQTS (LQT3) is associated with mutations in the cardiac sodium channel 
gene SCN5A. Some LQT3 mutations generate persistent, late sodium currents (INa,L).   
A single nucleotide polymorphism (SNP), i.e., R1193Q, was previously reported in a 
patient with drug-induced LQTS and further shown to be present in 0.2% of the general 
Caucasian population and nearly 12% of the Chinese population. SNP R1193Q mutation 
destabilizes inactivation gating of the cardiac sodium channel and generates INa,L that is 
expected to prolong the cardiac action potential duration (APD) and the QT interval on 
electrocardiogram (ECG). In order to study this mutation, our lab created a transgenic 
mouse line carrying human R1193Q mutant SCN5A. Using telemetry ECG analysis, I 
found that cardiac-specific expression of R1193Q results in prolongation of QT interval
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in transgenic mice (106.3 ± 9.47 ms, n = 7) compared to control groups of wild type mice 
(81.6 ± 14.12 ms, n = 5, p < 0.001) and transgenic wild type mice (78.0 ± 7.26 ms, n = 6, 
p < 0.001), demonstrating that R1193Q confers risk of prolonged QT interval, which 
potentially could be pro-arrhythmic. Moreover, in the presence of quinidine, R1193Q 
transgenic mice showed a higher incidence or premature atrial contractions (PACs), 
premature ventricular contractions (PVCs) and sinus atrial exit block (SAEB) than 
littermate wild type control mice and transgenic wild type mice. 
 In this study, I show that cardiac-specific expression of human R1193Q mutant 
SCN5A results in prolongation of QT interval in transgenic mice, which unequivocally 
demonstrates that R1193Q confers risk of prolonged QT interval, which is pro-arrhythmic. 
Moreover, in the presence of quinidine, R1193Q transgenic mice (TG-RQ) showed a 
higher incidence of premature ventricle contractions (PVCs) or premature atrial 
contractions (PACs) and AV block than littermate wild type control mice. These results 
suggest that R1193Q may increase the risk for drug-induced arrhythmias. Considering the 
high frequency of R1193Q in the general population, it may become necessary to perform 
population-wide screening for the variant to identify high risk individuals.  
 
2.2 Introduction 
Long QT syndrome (LQTS) is an a cardiac disorder characterized by prolonged QT 
interval on surface electrocardiogram (ECG), syncope and sudden death as a result of 
life-threatening ventricular tachycardia, specifically torsade de pointes (Wang et al 2004). 
Among them, type-3 long QT syndrome is caused by mutations in cardiac sodium 
channel gene SCN5A encoding type 5 voltage gated sodium channel α subunit, Nav1.5 
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(Wang et al 1995a). Nav1.5 is a large integral membrane protein which mediates the rapid 
upstroke of action potential in cardiac cells (George et al 1995).  
Acquired LQTS is generally drug-induced and frequently caused by therapeutic 
drug effects on ion channels involved in genetic forms of LQTS, such as blockage of the 
cardiac  potassium channels (Heist and Ruskin 2010). The missense mutation R1193Q 
was first identified in one of seven acquired LQTS patients. The electrophysiological 
study demonstrated that this mutation destabilizes inactivation gating and generates a 
persistent, non-inactivating sodium current in both transfected human kidney (HEK293) 
cells and Xenopus oocytes (Wang et al 2004). This SNP R1193Q presents in 0.2% in 
Caucasian general population and 12% in Chinese population (Hwang et al 2005, Wang 
et al 2004). Later, one group reported that SCN5A R1193Q polymorphism in a Chinese 
family was associated with progressive cardiac conduction defects and LQTS (Sun et al 
2008). 
Because some carriers with R1193Q have prolonged QTc, that my derivate in 
acquired LQTS and some have apparently normal QTc on surface ECG, it is necessary to  
demonstrate whether R1193Q confers a risk of QTc prolongation under action of drugs 
that can have the potential of prolonging the QT interval. The purpose of this study is to 
evaluate the ECG characteristic in transgenic mice carrying the high prevalence SNP 
R1193Q mutation, and the drug effects of quinidine, a class I anti-arrhythmic agent which 
also has class III properties, on this LQTS mouse model. 
 
2.3 Materials and Methods 
2.3.1 Preparation of Experimental Animals 
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This study was conducted in accordance with the guideline approved by the 
Cleveland Clinic Foundation Institutional Animal Care and Use Committee and was 
conformed to NIH guidelines.  
The strategy for generating transgenic mice carrying SNP R1193Q in SCN5A 
(TG-RQ) is similar to that used for developing transgenic mice which overexpress wild 
type SCN5A (TG-WT) (Tian et al 2004)or mutant SCN5A with the N1325S mutation 
(TG-NS) (Tian et al 2004, Tian and Wang 2006, Zhang et al 2011). In brief, a cDNA 
fragment of 6.2 kb human SCN5A (hSCN5A) with SNP R1193Q was subcloned behind 
the cardiac specific mouse myosin heavy chain-α (α-mMHC) promoter (5.4kb), and 
before a 0.6 kb human growth hormone polyadenylation signal sequence (hGH plA), 
resulting in a mMHC-hSCN5A construct. This construct was digested with Not I. A 12.4 
kb Not I fragment was purified by agarose gel electrophoresis and injected into fertilized 
eggs derived from the CBA/B6 mouse strain to yield founder mice. Founder mice were 
then bred to wild type mice to generate heterozygous TG-RQ mice. The experimental 
control mice in this study are non-transgenic wild type mice (denoted as NTG) or 
TG-WT as described previously (Tian et al 2004, Tian and Wang 2006, Tian et al 2007, 
Zhang et al 2011). 
Genotyping of positive TG-RQ mice was identical to that used for identifying 
TG-WT or TG-NS mice as previously described (Tian et al 2004, Tian and Wang 2006, 
Zhang et al 2007, Zhang et al 2011). In brief, mouse genomic DNA was isolated from 
clipped tail tissue samples when the pups were 10 days or younger. The tail tissue 
samples were collected in a 1.5 ml tube by adding 600 µl freshly prepared 50 mM NaOH. 
In order to fully digest the tissue samples, the mixture was heated on a heat block at 95oC 
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for one hour. After digestion, the mixture was placed on ice for 5 minutes and 50 µl of 
Tris-HCl buffer (pH = 8.0) was added. The mixture contained mouse genomic DNA and 
was ready to be used as DNA template for PCR-based genotyping. The primers for 
genotyping of TG-RQ mice were identical to those used for genotyping TG-WT and 
TG-NS mice and included 5’-TGT CCG GCG CTG TCC CTC TG-3’ (P1, forward) and 
5’-CTC ATG CCC TCA AAT CGT GAC AGA-3’ (P2, reverse) (Tian et al 2004).  
 
2.3.2 Western Blot Analysis 
Western blot analysis was performed to estimate the expression level of Nav1.5 in 
cardiac tissue samples from transgenic mice. Total protein extracts were extracted from 
the homogenized hearts using lysis buffer containing 20 mM Tris-HCl (pH = 8.0), 100 
mM NaCl, 1 mM EDTA and 0.5% NP-40. The concentration of protein extracts was 
measured using the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA) and all samples 
were diluted to the same concentration of 10 µg/µl. The protein extracts (100 µg) were 
separated by an 8% SDS-PAGE prepared with National Diagnostics ProtoGel solution 
(National Diagnostics, Atlanta, GA). After the separation, proteins were transferred to 
polyvinylidene difluoride membranes (Immun-blot PVDF membrane) (Bio-Rad, 
Hercules, CA) at 4 oC and 40V overnight. The membrane was blocked in 5% non-fat 
milk in PBST (phosphate-buffered saline, 0.05% (v/v) tween 20, pH=7.4) and then 
probed with an anti-rabbit Nav1.5 antibody (1:1000 dilution), followed by incubation 
with a horseradish peroxidase-conjugated secondary antibody (Santa Cruz, Santa Cruz, 
CA). The protein signal was visualized using the ECL Western blotting detection kit and 
Hyperfilm ECL (GE Healthcare, Pittsburgh, PA). The membrane was striped and blocked 
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with 5% non-fat milk in PBST, and was probed again using an anti-GAPDH antibody 
(Millipore, Billerica, MA), which serves as a loading control. 
 
2.3.3 Semi-Quantitative Real-Time PCR (RT-PCR) Analysis 
Total RNA samples were isolated from heart tissue samples from both NTG and 
TG-RQ mice in order to determine the expression level of SCN5A mRNA. Excised 
mouse hearts were placed into liquid nitrogen right after being washed with PBST. Total 
RNA samples were isolated using TRIzol reagent (Life Technologies, Grand Island, NY). 
For each heart sample, 1 ml of TRIzol reagent was applied, and the heart tissue was 
homogenized manually. After isolation, the RNA was immediately transcribed into cDNA 
using Stratagene’s RT-PCR kit (Agilent Technologies, Santa Clara, CA). Double-stranded 
cDNA was synthesized from 10 µg of total RNA. The semi-quantitative RT-PCR was 
used to quantify the RNA level. PCR primers were designed to amplify a region from 
exon 5 to 7 of the human SCN5A gene. The sequence of the forward primer is 5’- TGG 
AAC TGG CTG GAC TTT AGT GTG -3’, and the reverse primer is 5’-TGG TGC CGT 
TGA GCG CTG TGA AG -3’. RT-PCR analysis with 18S rRNA primers was used as 
internal control. The number of cycles for semi-quantitative RT-PCR was optimized for 
each sample to obtain data in the linear range for amplification. The PCR profile was 25 
cycles for SCN5A and 18 cycles for 18S rRNA. The PCR products were separated by a 
1.5% agarose gel and analyzed. 
 
2.3.4 Telemetry ECG Recordings 
Telemetry Electrocardiogram (ECG) Data from TG-RQ and control mice were 
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acquired using Data Sciences telemetry system (TA10ETA-F20 transmitter, Data 
Sciences International) with a receiver placed under each mouse cage. Mice (25-32g, 
6-10 months) were anesthetized with 20 mg/ml of Avertin (0.025 ml/g mice) 
(Sigma-Aldrich, St. Louis, MO). The abdomen hair was removed and the telemetry 
transmitter was then implanted into the mouse peritoneal cavity. The negative and the 
positive leads on the telemetry transmitter were surgically placed on the right shoulder 
and chest, respectively. The mice were observed for the first 48 hours after surgery, and 
ECG data were collected at least 48 hours after surgery using Data Sciences DATA 
Acquisition ECG software (Data Science International, St. Paul, MN). The QT interval 
was corrected for the RR interval using Bazett’s formula by QTc = QTo/(RR)1/2 (Bazett 
1920, Tian et al 2004, Zhang et al 2007) or the formula of QTc = QTo/(RR/100)1/2 as 
described previously (Mitchell et al 1998). 
 
2.3.5 Echocardiographic Assessment of Cardiac Structure and Function in 
Transgenic Mice 
The echocardiographic data were collected from TG-RQ and control mice (8-10 
month) as described previously (Zhang et al 2006). Each mouse had at least one 
echocardiography with the same handler. Echocardiography was performed using a high- 
frame rate (> 200 fps) echocardiography machine (GE Medicare, Milwaukee, WI) with 
14-MHz transducer coupled with an Applio ultrasopund machine (Toshiba, Japan).  
 
2.3.6 Data Analysis 
All the results were expressed as mean ± S.E.M., and the differences between 
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means were calculated by Student’s paired t-test. A P value of 0.05 or less is considered 
to be statistically significant. 
 
2.4 Results 
2.4.1 Generation and Identification of Transgenic Mice with Cardiac Specific 
Overexpression of Mutant Human SCN5A Gene with SNP R1193Q 
To determine whether SNP R1193Q in cardiac sodium channel gene SCN5A 
increases risk of LQTS, we generated TG-RQ transgenic mice with cardiac selective 
expression of mutant SCN5A with SNP R1193Q under the control of the mouse α-myosin 
heavy chain promoter, a cardiac-specific promoter (Figure 3A). Semi-quantitative real- 
time PCR analysis showed that TG-RQ mice expressed 5-fold more SCN5A mRNA in the 
heart tissue than control NTG mice (Figure 3B). Similarly, western blot analysis showed 
that TG-RQ mice expressed more than 3-fold more Nav1.5 protein in the heart than 
control NTG mice (Figure 3C). These results suggest that TG-RQ mice successfully 
overexpress mutant SCN5A with SNP R1193Q in the hearts. 
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Figure 3. Generation and Genotyping of TG-RQ Mice. (A) Transgenic construct for the 
engineering of transgene, RQ (SCN5A) (human SCN5A with acquired LQTS-associated SNP 
R1193Q), into the mouse genome. (B) Semi real-time PCR analysis was performed using heart 
tissue samples from non-transgenic mice and TG-RQ mice to estimate the SCN5A mRNA 
expression level in mouse hearts. SCN5A mRNA expression level in TG-RQ mice is 5-fold more 
than NTG. (C) Western blot analysis was performed using mouse hearts to estimate the protein 
expression level of SCN5A. SCN5A protein expression level is 3-fold more than NTG. 
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2.4.2 Development of Long-QT Syndrome in TG-RQ Mice 
I recorded ECGs from conscious and unrestrained mice using the telemetry 
monitoring system. Representative ECG traces for NTG, TG-WT and TG-RQ mice are 
shown in Figure 4A. The major ECG parameters were measured and compared among 
different groups of mice. Average QTc in TG-RQ mice was 106.3 ± 9.47 ms (n=7), which 
was significantly longer than that in either NTG mice (81.6 ± 14.12 ms, n=5) (P < 0.001) 
or TG-WT mice (78.0 ± 7.26 ms, n=6) (P < 0.001) (Figure 4B). These results suggest that 
SCN5A SNP R1193Q increases QTc in mice. Similar significant differences were 
obtained when QTc was calculated using either the Bazett’s formula by QTc = QT/(RR)1/2 
(Bazett 1920, Tian et al 2004, Zhang et al 2007) or the formula of QTc = QT/(RR/100)1/2 
as described previously (Mitchell et al 1998). 
The PR interval in TG-RQ mice (16.4 ± 1.55 ms) was similar to that in TG-WT 
mice (18.6 ± 2.37 ms) (P > 0.05), but significantly shorter than that in NTG mice (31.5 ± 
2.70 ms, P < 0.001) (Figure 4B). The QRS complex in all three groups of mouse lines 
had no significant differences (Figure 4B).  
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Figure 4. ECG Recordings of Non-transgenic (NTG), Transgenic Wild-type (TG-WT) 
and Transgenic R1193Q (TG-RQ) Mice. (A) Representative sample ECG traces from 
non-transgenic (NTG), TG-WT and TG-RQ mice. (B) Summary of ECG data analysis. 
QT intervals were corrected for heart rate as indicated as QTc. Statistical significance 
from control is denoted with an asterisk (*), whereas non-significance is indicated as NS. 
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2.4.3 Quinidine Prolonged QTc, and Increased the Frequencies of PACs, PVCs and 
Sinus Atrial Exit Block in TG-RQ Mice 
     SCN5A SNP R1193Q was identified in an acquired LQTS patient upon 
administration of quinidine(Wang et al 2004). Therefore, I tested whether quinidine could 
further increase QTc in TG-RQ mice. TG-RQ and control NTG mice were treated with 25 
mg/kg body weight of quinidine (i.p.), and ECGs were recorded using the telemetry ECG 
monitoring system. As shown in Figure 5, quinidine treatment significantly increased 
QTc in both TG-RQ and NTG mice 5 minutes after quinidine treatment, although 
quinidine diminished the QTc differences between these two groups. After quinidine 
treatment, QTc increased from 106.3 ± 9.47 ms to 128.1 ± 5.7 ms (n = 7, P < 0.05) in 
TG-RQ mice, and from 81.6 ± 14.12 ms to115.7 ± 6.2 ms (n= 5, P < 0.01) in NTG mice.  
TG-RQ mice remained to have significantly longer QTc 15 minutes and 25 minutes after 
treatment compared to control mice.   
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Figure 5. Quinidine Treatment Prolonged QTc in Both NTG (n=5) and TG-RQ Mice 
(n=7).  (A) Representative ECG traces before and after quinidine treatment in both NTG 
and TG-RQ mice. (B) Comparison of QTc before and after quinidine treatment. 
Quinidine treatment significantly prolonged QTc in both NTG and TG-RQ mice. *, P < 
0.05; **, P < 0.01; NS, not significant. 
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Representative ECG traces in TG-RQ mice after quinidine treatments are shown in 
Figure 6. The analysis of ECGs showed frequent premature atrial contractions (PACs), 
premature ventricular contractions (PVCs) and sinus atrial exit block (SAEB, or sinus 
node pause). The frequencies of PACs, PVCs and SAEB one hour before and after 
quinidine treatments were summarized in Table IV. Before quinidine treatments, no NTG 
mice (n = 5) showed any pro-arrhythmic ECG patterns, whereas three of seven TG-RQ 
mice showed PACs, PVCs, and SAEBs. However, after the application of quinidine, one 
NTG mouse showed a low frequency of PACs/PVCs, whereas five of seven TG-RQ mice 
developed PACs and PVCs. The frequencies of PACs and PVCs were much higher after 
quinidine treatments than before the treatments in TG-RQ mice. Moreover, three of seven 
TG-RQ mice developed SAEBs more than 25 times in one hour.  
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Figure 6. Quinidine Treatment Induced Increased PVCs, PACs, and SAEB in TG-RQ 
Mice.  
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Table IV. Effects of Quinidine Treatment on PACs, PVCs and SAEB in TG-RQ Mice 
and Control NTG Mice 
 
Mouse ID# 
Before Quinidine After Quinidine 
Number of PACs 
and PVCs 
Number of PACs 
and PVCs 
Number of SAEB 
NTG 1 0 2 0 
NTG 2 0 0 0 
NTG 3 0 0 0 
NTG 4 0 0 0 
NTG 5 0 0 0 
TG-RQ 1 0 4 26 
TG-RQ 2 2 6 0 
TG-RQ 3 2 9 0 
TG-RQ 4 2 16 0 
TG-RQ 5 0 5 2 
TG-RQ 6 0 0 > 30 
TG-RQ 7 0 0 > 30 
Notes: The number of PACs, PVCs and SAEB in a period of one hour before and after 
quinidine treatment was counted manually and summarized.   
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2.4.4 Echocardiographic Assessment of Cardiac Structure and Function in the Mice 
Because TG-NS mice developed dilated cardiomyopathy and heart failure at 
advanced ages as in human carriers with SCN5A mutation N1325S (Zhang et al 2011), 
echocardiography for TG-RQ mice was also performed, too. Basic echocardiographic 
parameters were compared between TG-RQ mice and control NTG mice (Table V).  
There were no significant structural differences between TG-RQ mice and NTG mice 
with regard to left ventricular fractional shortening (LVFS), systolic left ventricular end 
dimension (LVEDS), systolic intraventricular septum thickness (IVSS), left ventricular 
systolic posterior wall thickness (LVPWS), and other major echocardiographic 
parameters (Table V). These results suggest that SCN5A SNP R1193Q does not cause 
major structural changes in the heart.   
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Table V. Echocardiographic Assessment of Cardiac Function in TG-RQ Mice 
Parameter 
 
NTG (n=7) 
 
TG-RQ (n=7) 
 
P Value 
HR (bpm) 
 
638.3 ± 0.7 
 
672.4 ± 0.5 
 
0.59 
IVSD (mm) 
 
1.1 ± 0.08 
 
0.9 ± 0.03 
 
0.14 
IVSS (mm) 
 
1.8 ± 0.08 
 
1.6 ± 0.04 
 
0.09 
LVIDD (mm) 3.3 ± 0.1 
 
3.1 ± 0.1 
 
0.41 
LVIDS (mm) 1.5 ± 0.1 
 
1.5 ± 0.1 
 
0.8 
LVPWD (mm) 1.0 ± 0.09 
 
0.9 ± 0.06 
 
0.65 
LVPWS (mm) 1.5 ± 0.08 
 
1.5 ± 0.05 
 
0.73 
LVFS(%) 
 
57.0 ± 2.4 
 
51.0 ± 3.3 
 
0.18 
Notes: HR - heart rate; IVSD - left ventricular septum wall thickness in diastole; 
IVSS-left ventricular septal wall thickness in systole; LVEDD - left ventricular cavity 
size in diastole; LVEDS - left ventricular cavity size in systole; LVPWD - left ventricular 
posterior wall thickness in diastole; LVPWS - left ventricular posterior wall thickness in 
systole; LVFS - left ventricular fractional shortening, percent change in left ventricular 
cavity dimensions with systolic contraction. The mice used for echocardiography were at 
the age of 8 - 10 months.   
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2.5 Discussion 
     SNP R1193Q of SCN5A is a relatively high frequent variant in the general 
population, accounting for 0.2% the Caucasian population and 12% of the Chinese 
population (Hwang et al 2005, Wang et al 2004). SNP R1193Q was identified in one 
patient with drug-induced LQTS and follow-up electrophysiological studies demonstrated 
that it had similar functional effect on cardiac sodium channels as other types of 
LQTS-causing mutations such as N1325S. R1644H, and DelKPQ (Huang et al 2006, 
Wang et al 2004). Specifically, R1193Q can generate a late non-inactivation sodium 
current through an increased rate of dispersed reopening, which is predicted to prolong 
the cardiac action potential duration and QTc on ECGs (Huang et al 2006, Wang et al 
2004). However, genetic evidence for the association between SNP R1193Q and 
prolongation of QTc was not particularly strong. In this study, our lab established TG-RQ 
transgenic mice with cardiac specific expression of mutant human mutant SCN5A gene 
with the R1193Q SNP in mice. Telemetry ECG recordings showed that SNP R1193Q 
significantly increase QTc in TG-RQ mice compared to comparable control TG-WT or 
NTG mice (Figure 4). These data provide strong in vivo genetic data to support the 
hypothesis that SNP R1193Q of SCN5A can prolong QTc on surface ECGs.   
One carrier with SNP R1193Q developed acquired LQTS after administration of 
quinidine (Wang et al 2004). In this study, we found that quinidine increased QTc from 
TG-RQ mice (Figure 5). These data support that data from the human patient that 
quinidine can further prolong QTc from R1193Q carriers. Because quinidine increased 
QTc from both TG-RQ mice and control NTG mice (Figure 5), the relationship between 
genotype R1193Q and quinidine is additive with regard to the QTc phenotype, meaning 
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no epigenetic interaction between the two. We previously reported that although 
quinidine inhibited the peak sodium current form both wild type and R1193Q mutant 
sodium channels, but did not block the persistent late sodium current, which is more 
relevant to prolongation of QTc (Wang et al 2004). Therefore, quinidine may prolong 
QTc in TG-RQ mice or NTG mice by blocking outward potassium currents. The data 
from TG-RQ mice reinforce the notion that acquired LQTS represents a latent form of 
inherited LQTS because they share the similar genetic basis, but may manifest to the full 
LQTS upon additive effects of quinidine and other medications as well as other 
environmental factors (Wang et al 2004). A precaution should be taken when prescribing 
quinidine or other QT-prolonging drugs to patients carrying SNP R1193Q.   
In addition to in an acquired LQTS patient, SNP R1193Q was also identified in 
several patients with typical LQTS, Brugada syndrome, cardiac conduction disease, and 
sudden unexpected nocturnal death syndrome, and in a South Korean patient with LQTS, 
dilated cardiomyopathy, and sinus node pause (Huang et al 2006, Hwang et al 2005, 
Kwon et al 2012, Matsusue et al 2012, Qiu et al 2009, Skinner et al 2005, Sun et al 2008).  
Interestingly, I observed frequent SAEB or sinus node pause after administration of 
quinidine (Figure 6), a clinical feature observed in a Korean patient. No features related 
to dilated cardiomyopathy and Brugada syndrome were observed. No polymorphic 
ventricular tachyarrhythmia and sudden death were detected in TG-RQ mice, although an 
increased frequency of PACs and PVCs were found after administration of quinidine 
(Table IV). It remains to be determined whether human carriers with SNP R1193Q have 
increased PACs or PVCs.        
There are a few limitations with the present study. The first limitation is related to 
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the transgenic overexpression technology. Because LQTS-associated SCN5A mutations 
are gain of functions mutations including R1193Q that generate a persistent late sodium 
current, it is justified to overexpress R1193Q to investigate its effect on cardiac 
physiology. However, one disadvantage is that the observed phenotypes may be related to 
overexpression of sodium channels. For example, the shortened PR interval, development 
of PACs and PVCs, and depressed T waves may be due to overexpression of sodium 
channels because these phenotypes were observed in TG-WT mice, too (Zhang et al 
2007). Although utilization of TG-WT mice as control may eliminate these non-mutation 
specific effect, these factors need to be considered during interpretation of the data.  
Second, transgenic overexpression studies may exaggerate the mutant phenotype due to a 
higher number of the mutant SCN5A than the number of endogenous wild type SCN5A.  
Future studies with a knock-in model of R1193Q may be needed to mimic the human 
situation where there is only one copy of mutant SCN5A and one copy of the wild type 
gene.   
In conclusion, cardiac specific overexpression of mutant SCN5A with SNP1193Q 
led to increased QTc in transgenic mice (TG-RQ) compared to mice with cardiac specific 
overexpression of wild type SCN5A or NTG. Quinidine treatment can further increase 
QTc in TG-RQ, although it also increased QTc in control NTG control. Our data provide 
strong genetic evidence that R1193 can increase risk of LQTS and quinidine can further 
exaggerate the QT phenotype. Considering that 60,000 Americans and 156 million 
Chinese people are potential carriers of SNP R1193Q, this functional variant may be a 
significant risk factor for LQTS in the general population, in particular, under conditions 
of other QT-prolonging medications.     
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CHAPTER III 
 
LQTS MUTATION N1325S IN SCN5A CAUSES DISRUPTION OF CYTOSOLIC 
CALCIUM HOMEOSTASIS IN MOUSE VENTRICULAR MYOCYTES 
 
 
 
3.1 Abstract 
     The gain-of-function mutation N1325S in cardiac sodium channel gene SCN5A 
produces the late sodium current (INa,L) and is associated with type 3 long QT syndrome 
(LQT3), ventricular tachyarrhythmia (VT) and dilated cardiomyopathy (DCM) in both 
human and mice. An increased rate of apoptosis was also found in the hearts of transgenic 
mice expressing N1325S mutant human SCN5A (TG-NS). We hypothesized that INa,L 
their recoveries from caffeine applications, and Na+/Ca2+ exchanger (NCX) dysfunction 
in isolated TG-NS myocytes. Then, it was concluded that the loss of NCX activity 
confines cytosolic Ca2+ removal to SR Ca2+ reuptake and, thereby, prolongs Ca2+ recovery. 
To our knowledge, this is the first time to link the sodium channel mutation to abnormal 
Ca2+ handling. But there've been brought a lot of doubts about the linkage between INa,L
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and the abnormal Ca2+ transient by some reviewers. In order to further support the 
linkage between gain-of-function sodium channel mutations with abnormal Ca2+ handling, 
I have applied a late sodium current blocker, ranolazine, to isolated TG-NS myocytes in 
this study. The blockage of INa,L by ranolazine markedly reduced irregularity of the Ca
2+ 
transients and the recovery time from caffeine effect (indicated as T90r) in TG-NS 
myocytes. The rescue effect of ranolazine to abnormal Ca2+ handling provides additional 
evidence that a sodium channel mutation is the cause for abnormal Ca2+ handling in 
cardiomyocytes, which provides important insights into the pathogenic mechanisms of 
LQTS, VT and DCM. 
 
3.2 Introduction 
     In cardiac cells, the transient opening of Na+ channels gives rise to the inward 
current which is responsible for the upstroke of the cardiac action potential (AP) and 
initiation of excitation-contraction coupling (Li et al 1997, Liu et al 1992). After opening, 
most Na+ channels quickly enter an inactivated state. However, a small fraction of Na+ 
channel either fails to inactivate or to reopen during the plateau of the AP when the 
channels are normally closed. As a result, the outside Na+ ions continue to flow into the 
cell, and the influx of Na+ produces persistent or late Na+ currents (INa,L). Then, INa,L 
slows the repolarization of the AP and therefore increases the action potential duration 
(APD), proliferating heterogeneity of repolarization, and promoting the formation of 
early after-depolarizations (Kiyosue and Arita 1989).  
It is known that under an ischemia and/or reperfusion condition, where Na+ 
channel activation is impaired, INa,L contributes to a rise of myocardial Na
+ content in the 
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cells (Barrington et al 1997, Williams and Lisanti 2004). The increase of intracellular 
[Na+] can lead to intracellular Ca2+ overload via the dysfunction of Na+/Ca2+ exchanger 
(NCX), and these observations are consistent with the findings that an enhanced INa,L can 
lead to a Na+-dependent Ca2+ overload (Fraser et al 2006, Pieske et al 2002, Song et al 
2006, Wang et al 2008). 
N1325S mutation in the cardiac sodium channel gene SCN5A is associated with 
type 3 long QT syndrome (LQT3), which was originally identified in a 96-member 
family in 1995(Wang et al 1995a). In order to study this mutation, our lab has created a 
transgenic mouse model in two different lines (TG-NSL3 and TG-NSL12) that 
overexpress this NS mutation in the heart with different copy numbers. At the same time, 
a control model in two different lines (TG-WTL5 and TG-WTL10) that carry a similar 
copy number of wild type SCN5A in the heart was also generated. The resulting TG-NS 
phenotype of prolonged APDs in isolated ventricular cells, increased QTc, a high 
incidence of both ventricular tachyarrhythmias (VT) and sudden death has been reported 
previously (Tian et al 2004). Then follow-up studies in these TG-NS mice revealed 
co-development of dilated cardiomyopathy (DCM) and increased apoptosis and fibrosis 
(Zhang et al 2011). After these findings, in order to determine the mechanistic basis for 
this association, the Ca2+ handling was tested in isolated ventricular myocytes. The 
existence of cytosolic Ca2+ irregularities from TG-NS ventricular myocytes but not from 
TG-WT hearts is consistent with previous results that the heterogeneity of APD 
waveforms was effectively reduced in the presence of the L-type Ca2+ channel blocker, 
verapamil (Yong et al 2007). The major findings in isolated TG-NS ventricular myocytes 
include increased intracellular [Na+], Na+/Ca2+ exchanger dysfunction, and abnormal 
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Ca2+ handling. These findings are the first to demonstrate a direct link between SCN5A 
mutations and abnormal Ca2+ handling in cardiomyocytes. This potential link offers 
possible mechanisms into the high rate of apoptosis and fibrosis in TG-NS mice heart 
tissue and the existence of extracardiac diseases such as DCM. However, the 
up-regulation of some important Ca2+ handling proteins such as NCX, RyR2 and L-type 
Ca2+ channel in adult TG-NS mice hearts indicates the remodeling of the cardiomyocytes 
in the presence of N1325S mutation. In order to strengthen the direct linkage between 
this gain-of-function SCN5A mutation and abnormal Ca2+ handling, a late sodium current 
blocker, ranolazine (Antzelevitch et al 2011, Fredj et al 2006, Zaza et al 2008), was 
applied to the isolated myocytes. The rescue effect of ranolazine to the abnormal Ca2+ 
transient signals in TG-NS myocytes built a stronger bond between N1325S mutation and 
cytosolic Ca2+ irregularity. The possibility that the Ca2+ mishandling is caused by the 
remodeling of adult TG-NS myocytes is also diminished due to the ranolazine rescue 
effect. 
 
3.3 Methods and Materials 
     All experiments were conducted in accordance with the guidelines of the Cleveland 
Clinic Foundation Institutional Review Board on Animal Subjects and conformed to NIH 
guidelines. The generation and genotyping of TG-NSL3, TG-NSL12, TG-WTL5 and 
TG-WTL10 transgenic mice have been described previously (Tian et al 2004, Zhang et al 
2007).  
 
3.3.1 Isolation of Mouse Ventricular Myocytes 
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The isolation procedure of ventricular myocytes is similar to what has been 
previously reported (Tian et al 2004, Yong et al 2007). The mouse was heparinized with 
150 U (0.15ml of 1000 U/ml) of heparin via intraperitoneal (IP) injection 20 minutes 
before neck dislocation sacrifice. Then the mouse chest was quickly opened, and the heart 
was removed and washed with ice cold surgery buffer containing (in mM): 200, NaCl; 10, 
KCl; 5, MgCl2; 2, KH2PO4; 22, glucose; 50, HEPE; 4, CaCl2; 12.5, pyruvic acid; pH 
7.25 with NaOH. Next, under the microscope, the aorta of the heart was mounted on a 
syringe needle for Langendorff apparatus with a constant perfusion buffer flow rate of 
1.5ml/minute, and the aorta was secured with silk suture. The procedure should be 
finished within 5 minutes after the mouse was sacrificed. Before surgery, the Langendorff 
perfusion system was filled with perfusion solutions and cleared of air bubbles in order to 
prevent bubbles from entering the aorta during perfusion. The perfusion solutions were 
saturated with 95% O2:5% CO2 and warmed to 37
oC using a heated water bath. The 
cannulated heart was first washed with 100 ml first step Ca2+ containing perfusion buffer 
containing (in mM) 118, NaCl; 4.8, KCl; 2, CaCl2; 2.5, MgCl2; 1.2 KH2PO4; 11, glucose; 
13.8, NaHCO3; 4.9, pyruvic acid; PH 7.2. During this stage, a healthy and successful 
perfused heart should exhibit strong contraction and the blood in the heart chamber 
would be flooded out. After 3-minutes of washing with Ca2+ containing perfusion buffer, 
the heart was transferred to another perfusion system containing 60 ml second step 
Ca2+-free perfusion buffer. Then 45 mg of type II collagenase (Worthington, Lakewood, 
NJ) was added to second step Ca2+-free perfusion buffer once the heart stopped beating. 
Three minutes after adding collagenase, 1 mg of protease (Type XXIV, Sigma-Aldrich, St. 
Louis, MO) was added. Two sets of 0.1 mM CaCl2 was added 5 minutes (5 µl) and 10 
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minutes (10 µl) after applying collagenase. About 25 minutes after second step perfusion, 
the ventricle should appear yellowish and soft, and the digestion perfusion completed. 
The heart was placed in warm (~35oC) KB media buffer to reduce “Ca2+ paradox” 
(Isenberg and Klockner 1982), and the atrial appendages were carefully removed. Gentle 
tituration was performed in order to loosen the cells from the heart tissue. After tituration, 
a series of incremental increases in Ca2+ was made to a final Ca2+ concentration of 1.8 
mM. The cells are rested at room temperature for one hour before recordings. 
     The cells were split into two sets in order to test the rescue effects of ranolazine. 
The ranolazine was dissolved in PBST:DMSO (95:5) to 10 mM and saved as stock. One 
set of cells were incubated in 10 µM of ranolazine when “resting”, the other set of cell 
were incubated with same amount of blank PBST:DMSO (95:5) solvent that was used to 
dissolve ranolazine. 
 
3.3.2 Measurements of Ca2+ Transient Signals 
The Ca2+ transient signals were recorded according to the protocols reported 
previously (Lalli et al 2001, Ritter et al 2000, Rota et al 2005). Myocytes were loaded 
with 1 µM fura-2 acetoxymethyl ester (Fura-2-AM, Teflabs, Austin, TX) for 10 minutes 
at room temperature in the dark. Then the cells were centrifuged, and the buffer 
containing fura-2 was removed. Next, the cells were re-suspended in 3-4 ml of HEPE 
buffer and put in the dark.   
Before measurement, cells were transferred to the Bioptechs chamber (Bioptechs, 
Butler, PA) for which the temperature was set at 28oC. The initial field stimulation was 
set at 0.5 Hz and 5 ms duration. Ca2+ transients were measured using the same excitation 
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(340/380 nm) and emission (510 nm) spectra from the spectofluorometer. As an index of 
Ca2+ changes, the ratio of the emitted fluorescence at the wavelength of 340 nm over 380 
nm (F/Fo) was obtained. The steady-state Ca
2+ transient signals were recorded at a pacing 
frequency at 0.5 Hz in the absence of caffeine. The relative sarcoplasmic reticulum (SR) 
Ca2+ contents were estimated by the amplitudes of Ca2+ transient after the application of 
10 mM caffeine. The stimulation was stopped before adding caffeine. The resulting 
caffeine-induced Ca2+ transient (the amplitude from baseline to peak of the signal) was 
considered as a qualitative index of the SR Ca2+ content. The time for a caffeine-induced 
Ca2+ transient to recover by 90% from peak to baseline (T90r) was considered as the 
effectiveness of the SR and NCX in the myocytes to remove cytosolic Ca2+ back to SR or 
out of the cytoplasm. 
 
3.4 Results 
Irregular Ca2+ Transients in TG-NS Cardiomyocytes Can be Rescued by Late 
Sodium Current Blocker Ranolazine 
     According to the intracellular [Na+] measurement done by Dr. Yong in our lab, it 
was confirmed that the intracellular [Na+] in TG-NS myocytes was higher than in 
TG-WT myocytes. An increase in [Na+] can potentially lead to Ca2+ overload in the cells, 
perhaps through disrupting the cell’s ability to internally regulate Na+ and Ca2+ ionic 
homeostasis. Using Fura-2 AM method to estimate the intracellular Ca2+ from both 
TG-NS and TG-WT myocytes, an irregular Ca2+ handling was also observed in TG-NS 
myocytes which had longer recovery time when pacing at 0.5 Hz. Besides, the time to 90% 
recovery (T90r) of caffeine-induced Ca2+ transient signals was also longer in TG-NS 
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cells.  
     In order to link the abnormal Ca2+ transient signals in TG-NS myocytes to the 
presence of gain-of-function mutant Nav1.5, a late sodium blocker, ranolazine, was 
applied to the isolated TG-NS myocytes. Ranolazine is a blocker of the late sodium 
current caused by LQT3 mutation(Fredj et al 2006, Zaza et al 2008). The ranolazine 
treatment was performed in both isolated TG-NSL3 (Figure 7) and TG-NSL12 (Figure 8) 
myocytes. After 1 hour of ranolazine treatment, the Ca2+ transient signal has significant 
reduction (P < 0.05) in recovery time (T90r) (Figure 7E and Figure 8E) from caffeine 
effect with little or no changes in the transient amplitudes. Before ranolazine treatment, 
the myocytes in both TG-NSL3 (Figure 7A) and TG-NSL12 (Figure 8A) did not respond 
to the stimulation and the interval between each signal was irregular. However, in the 
presence of ranolazine, most isolated myocytes can respond to the stimulation (Figure 7C 
and Figure 8C) in the absence of caffeine. These results indicate that although ranolazine 
cannot reduce the higher SR Ca2+ storage significantly in TG-NS myocytes, it can reduce 
the time required for the removal of Ca2+ from the cytosol. This is consistent with the 
previous results that the SR Ca2+ content is not higher in TG-NS myocytes compared 
with TG-WT, but T90r is longer for TG-NS myocytes.  
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Figure 7. Ca2+ Transients Signals in Isolated TG-NSL3 Mice Myocytes (age=6-10 
months, n=14). (A & B) Representative Ca2+ transient recording in isolated TG-NSL3 
myocytes with (B) and without (A) 10 mM of caffeine. (C & D) Representative Ca2+ 
transient recording in isolated TG-NSL3 myocytes treated with 10 µM of ranolazine for 1 
hour with (D) and without (C) 10 mM of caffeine. (E) Summary of data from all the 
recordings. The time needed for recovery of caffeine-induced transient signal is 
significantly shortened after 10 µM of ranolazine treatment. *, P < 0.05 and **, P < 0.01 
indicates statistical significance. 
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Figure 8. Ca2+ Transients Signals in Isolated TG-NSL12 Mice Myocytes (age=6-10 
months, n=24). (A & B)  Representative Ca2+ transient recording in isolated TG-NSL12 
myocytes with (B) and without (A) 10mM caffeine. (C & D)  Representative Ca2+ 
transient recordings from isolated TG-NSL12 myocytes treated with 10 µM of ranolazine 
for 1 hour with (D) and without (C) 10 mM of caffeine. (E) Summary of data from all the 
recordings. The time needed for recovery of caffeine-induced transient signal is 
significantly shortened after 10 µM of ranolazine treatment. *, P < 0.05 and **, P < 0.01 
indicates statistical significance. 
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3.5 Discussion 
Previously, our lab has demonstrated that the LQTS-causing mutation N1325S in 
cardiac sodium channel gene SCN5A led to abnormal cytosolic Ca2+ transient signals in 
isolated single TG-NS ventricular myocytes. Then we have performed a series of 
experiments showing the intracellular [Na+]i increase and the dysfunction of Na
+/Ca2+ 
exchanger (NCX). These results gave us a potential mechanism that the abnormal Ca2+ 
handling in TG-NS cells is caused by this SCN5A gain-of-function mutation via 
dysfunction of NCX. To the best of our knowledge, this is the first study that provides a 
direct link between a SCN5A mutation and abnormal intracellular Ca2+ transient signaling. 
The comparison between TG-NSL12 and TG-WTL10 mice which express the wild-type 
human SCN5A gene and have the a similar copy number of the transgene revealed that 
only TG-NS myocytes showed this abnormal Ca2+ handling. Besides, another transgenic 
mouse line which carries less copy numbers of this mutant transgene, TG-NSL3, also 
exhibited irregularities in Ca2+ transient signals, albeit with less severity. All these 
observations indicate that it is the mutation N1325S, rather than the overexpression of 
SCN5A, that caused the Ca2+ transient abnormality. 
     Our lab has also studied the expression level of the important Ca2+ handling proteins 
in TG-NS mouse hearts using Western blot analysis. The up-regulation of L-type Ca2+ 
channel protein, NCX and RyR2 in the presence of N1325S mutation suggests the 
remodeling of TG-NS myocytes. The changes in the Ca2+ handling proteins weaken the 
linkage between SCN5A mutation and abnormal Ca2+ handling we have set based on 
intracellular [Na+] increase and NCX dysfunction. In order to further investigate the 
relationship between this gain-of-function mutation and the abnormal Ca2+ handling in 
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the TG-NS myocytes, we introduced the LQTS drug, ranolazine, to block the late sodium 
current produced by N1325S mutation. After 1 hour of 10 µM ranolazine treatment, the 
abnormal Ca2+ transient signal in the isolated TG-NSL3 and TG-NSL12 ventricular 
myocytes can be successfully rescued. This rescue effect further strengthened the direct 
linkage between N1325S mutation and abnormal Ca2+ handling. 
     In the previous study of Ca2+ transient signals in TG-NS ventricular myocytes, the 
most remarkable Ca2+ transient irregularity in TG-NS cells was in response to caffeine 
application though the amplitudes of the caffeine-induced Ca2+ transients did not have 
significant differences when compared to TG-WT cells. The prolongation of the recovery 
rate was often characterized by oscillations or “re-excitations” in TG-NS cells, and this 
characterization was also observed in HL-1 cells expressing N1325S mutant human 
SCN5A gene. These results suggested that the Ca2+ abnormalities in TG-NS ventricular 
myocytes may not stem from an “excess” of SR Ca2+ ion content but rather from a 
weakened ability to recover the cytosolic Ca2+ concentration to baseline. According to 
Ca2+ handling study in cardiac cells, the decline of intracellular Ca2+ ions during a 
caffeine-induced SR-Ca2+ release is almost entirely due to the extrusion of the Ca2+ via 
NCX (Altamirano et al 2006, Picht et al 2007). The interesting finding is that the 
expression of NCX-1 is increased in TG-NS mouse hearts, which seems to be 
contradictory to our findings in Ca2+ handling. Whereas, it is believed that NCX-1 
expression level increase is a response to this chronic elevation of cytosolic Ca2+ in 
TG-NS myocytes. In the presence of N1325S mutant SCN5A gene, both intracellular Na+ 
and Ca2+ increase. It is hypothesized that the excess of Na+ and Ca2+ forces an adaptive 
response of the TG-NS cells in which the NCX is impossible to work in its proper way. 
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The lack of NCX current in TG-NS myocytes gives us a strong support to our hypothesis. 
As a result, in order to compensate dysfunction of NCX, more NCX-1 will be expressed 
in TG-NS myocytes. 
     Based on the result of our experiments, the ranolazine treatment to isolated 
TG-NSL3 and TG-NSL12 ventricular myocytes can significantly reduce the recovery 
time of caffeine-induced Ca2+ transients. It suggests that one hour, 10 µM ranolazine 
treatment is enough to recover the NCX function. The excess Na+ entry caused by INa,L is 
reduced using this late sodium blocker ranolazine, and the application of ranolazine can 
improve Ca2+ homeostasis.  
     In conclusion, this study has established the link between the existence of cytosolic 
Ca2+ inhomogeneity in TG-NS ventricular murine myocytes and the presence of a 
gain-of-function LQTS mutation N1325S in human cardiac sodium channel gene SCN5A, 
which is known to generate late sodium current INa,L. The application of INa,L blocker 
ranolazine is proved to successfully rescue the abnormal Ca2+ handling in TG-NS mouse 
ventricular myocytes. This finding along with the intracellular Ca2+ abnormality in the 
presence of SCN5A mutation N1325S may provide a molecular mechanism for 
development of VT and DCM in both TG-NS mice and human patients with SCN5A 
mutations. 
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CHAPTER IV 
 
LATE SODIUM CURRENT PRODUCED BY GAIN-OF-FUNCTION LQTS 
MUTATIONS IN CARDIAC SODIUM CHANNEL LEADS TO ABNORMAL 
CALCIUM HANDLING IN CARDIAC CELLS 
 
 
 
4.1 Abstract 
N1325S mutation in the cardiac sodium channel gene SCN5A produces late sodium 
currents (INa,L) and is associated with type-3 long QT syndrome (LQTS), ventricular 
tachyarrhythmias (VT) and dilated cardiomyopathy (DCM) in both human and mice. 
However, the underlying molecular mechanisms that originated from INa,L need to be 
further explored. In this study, I have successfully correlated the mutant SCN5A with 
abnormal Ca2+ transient signals in transfected HL-1 cells. In HL-1 cells expressing 
N1325S mutant human SCN5A, the caffeine-induced Ca2+ transient signal showed 
significant prolonged recovery time from caffeine effects compared with cells expressing 
wild type human sodium channel Nav1.5. This result indicates the reduced ability to 
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re-uptake the cytosolic Ca2+ of SR or to remove extra intracellular Ca2+ out of the cell in 
the presence of mutant Nav1.5. Based on these observations, I hypothesized that INa,L 
leads to cytosolic Ca2+abnormalities. In order to test my hypothesis, I treated the cells 
with late sodium current blockers, ranolazine and mexiletine, and test if the abnormal 
Ca2+ handling can be rescued. The experiment results confirmed that both blockers was 
able to shorten the time required to remove the cytosolic Ca2+ from caffeine effects with 
no significant reduction in peak Ca2+ response. In order to further test my hypothesis, I 
then selected several other SCN5A mutations that can either cause LQTS or Brugada 
syndrome for SCN5A mutation classification. In this experiment, I measured the Ca2+ 
transients and time of recovery from caffeine in these mutations. After measurements, the 
results were compared in different types of Nav1.5 mutations. The mutation classification 
results further indicated the correlation between the late sodium current and the weakened 
ability of the cell to reduce the cytosolic Ca2+. Taken together, this study first correlates 
sodium mutations with Ca2+ handling in cardiac cells, and it can provide us important 
insights into the pathogenic mechanisms of LQTS, VT and DCM. 
 
4.2 Introduction 
The transient opening of Na+ channels in cardiac cells gives rise to the inward 
current responsible for the upstroke of the cardiac action potential (AP) and the initiation 
of excitation-contraction coupling (Kiyosue and Arita 1989, Li et al 1997, Liu et al 1992). 
The changes in cardiac AP are composed of 5 phases from 0 to 4 and the opening of 
sodium channel contributes to rapid depolarization phase 0 and the plateau phase 2. After 
opening, sodium channels enter an inactivated state. However, gain-of-function mutant 
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sodium channels will stay at the inactivated state during the plateau (phase 2) of the AP 
when the wild type channels are usually closed. The abnormal prolonged inactivated state 
of the sodium channels will allow the continuous flow of Na+ into the cell and results in 
persistent late sodium current (INa,L). Accordingly, the presence of INa,L slows down the 
repolarization of the cell and therefore increases action potential duration (APD) (Liu et 
al 1992). 
It is known that under ischemia/reperfusion conditions, sodium channel activation 
in cardiac cells is impaired, and that leads to INa,L. Consequently, INa,L will cause the rise 
of myocardial Na+ content (Barrington et al 1997, Williams et al 2007). The increase of 
intracellular Na+ content can lead to increased Ca2+ via Na+/Ca2+ exchanger (NCX), 
which is consistent with the findings that INa,L leads to a Na
+-dependent Ca2+ overload 
(Fraser et al 2006, Pieske et al 2002, Song et al 2006, Wang et al 2008). 
N1325S mutation in cardiac sodium channel SCN5A gene is a type-3 long QT 
syndrome mutation and was originally identified in a 96-member family (Wang et al 
1995a). Previously, our lab generated a transgenic mouse model that overexpresses 
N1325S mutant human SCN5A in the heart (TG-NSL3 and TG-NSL12). According to the 
prior results, INa,L produced by this gain-of-function LQTS mutation results in prolonged 
APDs in isolated ventricular myocytes, increased QTc on electrocardiograms and a high 
incidence of both ventricular tachyarrhythmias (VT) and sudden death in both TG-NSL3 
and TG-NSL12 mice (Tian et al 2004). Besides, Dr. Sandro Yong in our lab has found 
that the Ca2+ transient signal is abnormal in isolated TG-NS myocytes due to the elevated 
intracellular Na+ concentration and Na+/Ca2+ dysfunction. All these findings in TG-NS 
mice demonstrate a potential mechanism that can explain the pathogenesis of this 
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mutation. However, there is one more problem to be solved before we come up with the 
conclusion. In TG-NS myocytes, some important Ca2+ handling proteins, e.g., NCX, 
RyR2 and L-type Ca2+ channel, are up-regulated in the presence of N1325S mutation 
(Zhang et al 2011). The up-regulation of these proteins indicates the remodeling of adult 
TG-NS myocytes caused by the mutant SCN5A transgene.  
In order to overcome the adult myocytes remodeling problem, I introduced HL-1 
cells, a cardiac muscle cell line derived from AT-1 mouse atrial cardiomyocyte tumor 
lineage, in this study (Claycomb et al 1998). In HL-1 cells expressing N1325S mutant 
SCN5A gene, the time required to remove extra cytosolic Ca2+ induced by caffeine is 
significantly prolonged compared with cells expressing wild type SCN5A gene. The 
further study of the effect for the blockage of INa,L on abnormal Ca
2+ handling provides us 
more evidences that INa,L correlates with Ca
2+ handling abnormality in cardiac cells 
expressing gain-of-function mutant Nav1.5. The linkage between SCN5A mutation and 
abnormal Ca2+ handling offers a potential mechanism for LQTS and cardiac arrhythmias. 
 
4.3 Materials and Methods 
4.3.1 HL-1 Cardiac Cell Culture 
HL-1 cardiac cell was a gift from Dr. William Claycomb (Louisiana State 
University, Medical Center, New Orleans, LA). According to the instruction from Dr. 
Claycomb, the cells were cultured in 5% CO2 at 37
oC in Claycomb media 
(Sigma-Aldrich, St. Louis, MO) supplemented with batch-specific 10% FBS (Sigma- 
Aldrich, St. Louis, MO), 100 U-100 µg/ml penicillin-streptomycin (medium room at 
Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH), 2 mM L- 
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glutamine (medium room at Lerner Research Institute, Cleveland Clinic Foundation, 
Cleveland, OH), and 0.1 mM norepinephrine (Sigma-Aldrich, St. Louis, MO). Before 
plating HL-1 cells, all the culture flasks and dishes were pre-treated for overnight with 
fibronectin/gelatin coating buffer containing 0.02% gelatin (ThermoFisher Scientific, 
Austin, TX) with 0.5% fibronectin (Life Technologies, Grand Island, NY).  
 
4.3.2 Na+ Channel Cloning and Site-Directed Mutagenesis 
Both wild type (WT) and mutant human cardiac SCN5A constructs were generated 
as described in the previous study (Wan et al 2001). All the plasmids were prepared at the 
same time using plasmid Maxi Prep (QIAGEN, Valencia, CA). 
 
4.3.3 Transient Transfection of HL-1 Cell 
HL-1 cardiac cells were transfected with either wild-type (WT) or mutant SCN5A 
expression plasmids along with GFP as an indicator for transfected cells using the PolyJet 
DNA In Vitro Transfection Reagent (SignaGen Laboratories, Gaithersburg, MD) 
according to the manufacturer’s instructions with minor modifications to optimize the 
transfection efficiency. For Ca2+ transient measurements, HL-1 cells were plated on 12 
mm diameter glass coverslips (Life Technologies, Grand Island, NY) at a density of 3 × 
105 cells/ well in a 12-well culture plate (Sigma-Aldrich, St. Louis, MO). For each well, 
the amount of plasmid DNA and PolyJet reagent used for transfection is 1 µg and 3 µL, 
respectively. The transfected HL-1 cells were ready for Ca2+ transient measurements 48 
hours after transfection. 
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4.3.4 Intracellular Ca2+ Transient Measurements 
Before Ca2+ transient measurements, the transfected HL-1 cardiac cells were 
incubated with 10 µM Fura-2 acetoxymethyl ester (Fura-2/AM, TEFlabs, Austin, TX) for 
10 minutes at room temperature in the dark. The cells were then washed with the fresh 
complemented Claycomb medium and incubated at 37oC with 5% CO2 for 20 min to 
make sure that the acetoxymethyl group in Fura-2/AM is completely removed by cellular 
esterase. The coverslips containing HL-1 cells were then transferred to a Bioptech 
chamber on the microscopic stage at 28oC, and initial field stimulation was set at 0.5 Hz 
and 5 ms duration during measurement. Ca2+ transient was measured simultaneously in 
20-30 cells using excitation (340/380 nm) and emission (510 nm) spectra from the 
spectofluorometer with a fixed test field. As an index of Ca2+ changes, the ratio of the 
emitted fluorescence at the wavelength of 340nm over 380nm (F/Fo) was calculated. 
Steady state Ca2+ transient signals were obtained at a pacing frequency of 0.25 Hz in the 
absence of caffeine. The relative sarcoplasmic reticulum (SR) Ca2+ contents of HL-1 
cardiac cells expressing both WT and mutant SCN5A were estimated by comparing the 
amplitudes of Ca2+ transients before and after the application of 10mM caffeine, and the 
time needed for 90% recovery from caffeine application was calculated. The stimulation 
was stopped before 10 mM caffeine application. The rescue effects of late sodium current 
blockers were tested in the presence of 10 µM ranolazine and 10 µM mexiletine after one 
hour treatment at 37oC with 5% CO2. 
 
4.3.5 Data Analysis 
All the results were expressed as mean ± S.E.M., and the differences between 
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means were calculated by student’s paired t-test. A value of P < 0.05 was considered as 
statistically significant. 
 
4.4 Results 
4.4.1 N1325S Mutant Sodium Channels Lead to Irregular Ca2+ Handling in HL-1 
Cells 
In order to evaluate the effects of gain-of-function mutation N1325S in SCN5A 
gene to the cardiac Ca2+ handling, the HL-1 cells were transfected with wild-type (WT) 
or N1325S mutant SCN5A and used to assess the cytosolic Ca2+ levels using the Fura-2 
AM. In excited HL-1 cells expressing the N1325S mutation, I found the premature or 
re-excited Ca2+ transient signals, which did not respond accordingly to the stimulation at 
a 0.25 Hz frequency. This abnormal Ca2+ transient signals indicate that the cytosolic Ca2+ 
in HL-1 cells expressing N1325S mutant SCN5A has difficulties in returning to baseline 
under 0.25 Hz stimulation frequency.  
In order to further estimate the SR Ca2+ storage in mutant cells, I acutely treated the 
transfected cells with 10 mM caffeine. Caffeine is commonly used to estimate the content 
of the SR Ca+ storage, Ca2+ release, and the rate of Ca2+ extrusion from the cells (Picht et 
al 2006). In this experiment, I observed a significant increase in the amplitude and 
duration of Ca2+ release after adding caffeine (10 mM) to the cells (Figure 9C) in HL-1 
cells expressing N1325S mutant SCN5A. The amplitude of the Ca2+ transient in response 
to caffeine is often an index of the SR Ca2+ content during diastole (Lewartowski and 
Zdanowski 1990). In HL-1 cells expressing N1325S mutant SCN5A, the higher Ca2+ 
transient amplitudes comparing with HL-1 cells expressing WT SCN5A indicate a higher 
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SR Ca2+ content during diastole (F/Fo value: 0.53 ± 0.03 in N1325S and 0.35 ± 0.03 in 
WT, P < 0.05). At the same time, the time required for Ca2+ transients returning to 
baseline in response to caffeine is higher in cells expressing N1325S mutation than in 
control cells (20.5 ± 1.9 s in N1325S and 14.7 ± 0.8 s in WT, P < 0.05). These results 
indicate that compared with cells expressing WT SCN5A, HL-1 cells with the N1325S 
mutation have higher initial SR Ca2+ content, and slower removal of Ca2+ from the 
cytosol compared with WT cells. Besides, in some HL-1 cells expressing the N1325S 
mutation, there are a second caffeine-induced Ca2+ responses (Figure 9D). This 
phenomenon can be explained by re-excitation by elevated cytosolic Ca2+ concentrations 
of the cells during repolarization. The sustained high cytosolic Ca2+ causes the release of 
SR Ca2+ storage more than once during one excitation-contraction coupling. 
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Figure 9. Ca2+ Transients Signals in Transfected HL-1 Cells. (A) Representative Ca2+ 
transient recordings in HL-1 cells expressing N1325S mutation in SCN5A gene with 
(right) and without (left) 10 mM of caffeine. (B) Representative Ca2+ transient recordings 
in HL-1 cells expressing wild type SCN5A gene with (right) and without (left) 10 mM 
caffeine. (C) Summary of data from all the recordings. The caffeine-induced peak Ca2+ 
response is higher in N1325S HL-1 cells (upper right). The time needed for recovery 
from caffeine effect is also significantly prolonged in HL-1 cells expressing N1325S 
mutant SCN5A gene. (D) Representative Ca2+ transient signals with re-excitation after 
adding caffeine. *, P < 0.05 indicates statistical significance. 
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4.4.2 Ranolazine Can Reduce the SR Ca2+ Content and Strengthen the Ability of 
Removing Extra Cytosolic Ca2+ in HL-1 Cells Expressing N1325S Mutant 
SCN5A 
     N1325S mutation is a gain-of-function mutation in SCN5A that can produce 
persistent late sodium currents (Tian et al 2004). In the isolated myocytes from transgenic 
mice carrying N1325S mutation (TG-NS), the intracellular Na+ concentration is higher 
compared with non-transgenic (NTG) and transgenic wild type (TG-WT) mice. During 
the excitation-contraction coupling in the cardiac cells, Ca2+ ions are extruded from the 
cells mainly via the Na+/Ca2+ exchanger in order to reduce the cytosolic Ca2+ after 
diastole (Bers 2002). In our TG-NS mouse myocytes, the lack of Ni+-sensitive current 
indicated that Na+/Ca2+ exchanger is dysfunctional (Yong S, unpublished data). These 
two findings in our TG-NS mice provided a direct link between a SCN5A mutation and 
the abnormal intracellular Ca2+ signaling. However, the up-regulation of some Ca2+ 
handling proteins such as NCX, RyR2 and L-type Ca2+ channel indicated the remodeling 
of the cardiac cells in adult TG-NS mice (Zhang et al 2011). The lack of mature cardiac 
cell phenotype in neonatal cardiomyocytes limits the use of isolated neonatal myocytes in 
TG-NS mice. In this study, the introduction of HL-1 cells overcame the remodeling 
problem in adult TG-NS mice.  
     To correlate the effects of late sodium current and abnormal Ca2+ handling, the 
cells were treated with 10 µM of ranolazine (Figure 10) to block the late sodium currents. 
Ranolazine is a investigative anti-arrhythmic drug in phase III trials. It has been approved 
that ranolazine can successfully block the late sodium currents caused by LQT3 
mutations in the SCN5A gene (Fredj et al 2006, Zaza et al 2008). After 1 hour of 
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ranolazine treatment, I observed that the Ca2+ transient signal showed significant 
reduction from 20.5 ± 1.9 s to 12.9 ± 1.7 s (P < 0.05) in recovery time (T90) (Figure 10F) 
from caffeine effect with little or no changes in the transient amplitudes (Figure 10D). 
Besides, in the presence of ranolazine, most abnormal transient signals can also be 
rescued to normal and can respond to the stimulation accordingly (Figure 10A and 10B). 
These results indicate that although ranolazine cannot reduce the higher SR Ca2+ storage 
significantly in N1325S mutant HL-1 cells (Figure 10D), it can reduce the time required 
for the removal of Ca2+ from the cytosol (Figure 10F). Therefore, according to my results, 
the treatment of ranolazine itself is not enough to reduce the SR Ca2+ content significantly. 
However, the shortening of time that is required for the removal of Ca2+ from cytosol can 
explain the potential mechanism why ranolazine is an effective treatment for LQT3 
patients. Consequently, after successful blockage of late sodium currents by ranolazine, 
the elevated intracellular Na+ concentration is reduced, and the dysfunction of NCX is 
rescued. Note that during the excitation-contraction coupling in the cardiac cells, Ca2+ 
ions are extruded from the cells mainly via the Na+/Ca2+ exchanger in order to reduce the 
cytosolic Ca2+ after diastole (Bers 2002). The re-gaining function of NCX increases the 
ability of the cell to extrude cytosolic Ca2+.  
     Furthermore, ranolazine treatment was not able to decrease the caffeine-induced 
peak Ca2+ responses (Figure 10D). One of the excitation-contraction coupling model 
proposed that the SR Ca2+ is stored in two compartments: an uptake compartment and a 
release compartment (Euler 1999). Thus, the caffeine-induced peak Ca2+ response may 
not be determined by the total SR Ca2+ content, but the Ca2+ content available to be 
released in the release compartment. The ranolazine treatment for one hour is not enough 
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to break the “balance” between uptake compartment and release compartment Ca2+ 
content in SR, thus it would not change the peak Ca2+ response in the presence of 10 mM 
caffeine. 
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Figure 10. Effect of Ranolazine Treatments in HL-1 Cells Expressing the N1325S 
Mutation. (A) Representative Ca2+ transient recordings in HL-1 cells carrying the 
N1325S mutation before (left) and after (right) caffeine. (B) Reprensentative Ca2+ 
transient recording in HL-1 cells carrying the N1325S mutation in the presence of 10 µM 
of ranolazine treatment before (left) and after (right) caffeine. (C-F) Summary of data 
from all the recordings. The time needed for the removal of cytosolic Ca2+ after caffeine 
is shortened after ranolazine treatment. *, P < 0.05 indicates statistical significance. 
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4.4.3 Mexiletine Can Reduce the SR Ca2+ Content in HL-1 Cells Expressing 
N1325S Mutant SCN5A 
In this study, another late sodium current blocker mexiletine was also tested in 
N1325S mutant HL-1 cells. Mexiletine can abbreviate the QT interval in LQT3 patients 
(Sicouri et al 1997). Our lab previously reported that mexiletine was able to successfully 
block the late sodium current in isolated TG-NS myocytes (Tian et al 2004). Mexiletine 
can also suppress ventricular fibrillation (VF) and ventricular tachycardia (VT) in TG-RQ 
mice (Tian et al 2004). In this study, I identified that similar to ranolazine, in the presence 
of 10 µM of mexiletine, the recovery time from caffeine is significantly reduced by ~50% 
from more than 20 seconds to 10.6 ± 1.4 s (P < 0.05) (Figure 11F). And also similar to 
ranolazine, mexiletine treatment is also not able to reduce the caffeine-induced Ca2+ peak 
response (Figure 11E). And the cells can respond to the stimulation better after treatment 
(Figure 11A and 11B). 
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Figure 11. Effect of Mexiletine Treatments in HL-1 Cells Expressing the N1325S 
Mutation. (A) Representative Ca2+ transient recordings in HL-1 cells carrying the 
N1325S mutation before (left) and after (right) caffeine. (B) Reprensentative Ca2+ 
transient recording in HL-1 cells carrying the N1325S mutation in the presence of 10 µM 
of mexiletine treatment before (left) and after (right) caffeine. (C-F) Summary of data 
from all the recordings. The time needed for the removal of cytosolic Ca2+ after caffeine 
is shortened after mexiletine treatment. *, P < 0.05 indicates statistical significance. 
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4.4.4 Classification of Different SCN5A Mutations 
Since LQTS mutation N1325S showed these Ca2+ transient signal specific features 
in both isolated myocytes and transfected HL-1 cells, I was wondering if other 
gain-of-function mutations in SCN5A will display the same phenotype or it is just 
N1325S specific phenomenon. In the next series of experiments, I have selected other 
two LQTS mutations in SCN5A gene, E1784K and ΔKPQ, which also produce late 
sodium currents like N1325S mutation (Dumaine et al 1996, Wei et al 1999). At the same 
time, I selected two Brugada syndrome mutations, A1924T and L567Q, which do not 
produce the late sodium current (Rook et al 1999, Wan et al 2001). In this experiment, I 
only evaluated the effects from caffeine effects to estimate the content of SR Ca2+ storage 
and the recovery time required to remove extra cytosolic Ca2+ (Figure 12). After 
statistical analysis, I found that both E1784K and ΔKPQ mutations can significantly 
prolong the recovery time from caffeine, and the prolongation of E1784K mutation is 
almost 10 times as much as wild type sodium channel (Figure 12C). The caffeine-induced 
peak Ca2+ response in N1325S, ΔKPQ, E1784K and A1924T are all significantly higher 
than HL-1 cells transfected with WT SCN5A (Figure 12B). According to my results, the 
caffeine-induced peak Ca2+ response is not correlated with the presence of LQTS 
mutations (Figure 12B). The reason behind this could be explained by the two SR 
compartments theory(Euler 1999). During excitation-contraction coupling, the cells 
expressing LQTS mutant SCN5A experience a spontaneous Ca2+ oscillation, and no 
sufficient time for the cells to transfer the uptake compartment Ca2+ to release 
compartment in SR. As a result, the Ca2+ content in release compartment is limited and 
not be able to reflect the total SR Ca2+ content. This theory about SR Ca2+ storage can  
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Figure 12. Effects of Different SCN5A Mutations on Ca2+ Transients. (A) Representative 
Ca2+ signal response induced by 10 mM of caffeine. (B) The peak Ca2+ response in 
different mutations related to wild type SCN5A (100%). Three mutations, N1325S, ΔKPQ 
and A1924T have higher peak Ca2+ response compared with wild type sodium channels. 
(C) Time required for 90% recovery in the intracellular Ca2+ from caffeine effect. Three 
mutations, N1325S, ΔKPQ and E1784K which are all LQTS mutations producing late 
sodium currents need significantly longer 90% transient recovery time. *, P < 0.05 and 
**, P < 0.01 indicate statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
E1784K A1924T L567QΔKPQWT N1325S
** **
**180
160
140
120
100
80
60
40
20
0
Pe
ak
 C
a2
+
re
sp
on
se
 (%
) 180
160
140
120
100
80
60
40
20
0
90
%
Tr
an
sie
nt
re
co
ve
ry
 (s
ec
)
**
**
*
A
B C
89 
 
explain why the caffeine-induced peak Ca2+ response is not always higher in LQTS 
mutant cells. Except for Na2+ content, the amount of Ca2+ in SR release compartment is 
affected by other factors or it is a result of complex factors. 
 
4.4.5 Ranolazine Effect in Various SCN5A Mutations 
In order to further test the relationship between different types of SCN5A mutations 
and Ca2+ handling, the ranolazine effect in these mutations was also tested (Figure 13). 
After one hour, 10 µM of ranolazine treatment, the Ca2+ transient signals were collected 
in HL-1 cells transfected with different SCN5A mutations and wild-type SCN5A. As I 
expected, the 90% transient recovery time from caffeine was significantly reduced in the 
mutations (N1325S, ΔKPQ and E1784K) that can produce certain amount of late sodium 
currents (Figure 13C). The shortening of recovery time from caffeine is especially 
dramatic in E1784K mutation, from 132.67 seconds (n=8) to an average of 13.877 
seconds (n=10). At the same time, the peak Ca2+ response from caffeine in E1784K 
mutation is more than 300% compared with wild-type SCN5A (Figure 13B). This 
significantly higher peak Ca2+ response from caffeine in E1784K mutation indicates an 
increase of release Ca2+ content in SR after ranolazine treatment. One of the Brugada 
mutations, L567Q, also showed significantly increased peak Ca2+ response in the 
presence of caffeine, but the mechanism behind this is not clear and need to be further 
explored (Figure 13B).  
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Figure 13. Effect of Ranolazine in Various SCN5A Mutations. (A) Representative Ca2+ 
signal induced by 10 mM caffeine after 1 hour, 10 µM ranolazine treatment. (B) The peak 
Ca2+ response in different mutations related to wild type SCN5A (100%) after ranolazine 
treatment. One of the LQTS mutations, E1784K, has significantly increased response 
compared with WT. One of the Brugada mutations, L567Q, has dramatically stronger 
caffeine response compared with WT. (C) Time required for 90% recovery in the 
intracellular Ca2+ from caffeine effect. After one hour, 10 µM ranolazine treatment, all the 
LQTS mutations studied in this experiment showed no significant differences compared 
with WT. *, P < 0.05 and **, P < 0.01 indicate statistical significance.  
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4.5 Discussion 
     In this study, I introduced transfected HL-1 cells for Ca2+ handling study related to 
Nav1.5 mutations for the first time. The results in this study demonstrate that 
gain-of-function LQTS causing mutation, N1325S, in cardiac sodium channel gene 
SCN5A leads to abnormal cytosolic Ca2+ transient signal in HL-1 cells. This Ca2+ 
handling study correlates the sodium mutations with abnormal intracellular Ca2+ in the 
cardiac cells. The electrophysiological study of transgenic mice is time consuming, and 
the isolation for adult mice cardiomyocytes depends on the quality of the collagenase 
from the commercial companies. The introduction of HL-1 cells will solve the adult 
myocytes remodeling problems because HL-1 cells are easy to be transfected and can 
retain the adult cardiomyocyte phenotype in culture.   
In this study, I found that the caffeine-induced peak Ca2+ transients in HL-1 cells 
expressing N1325S mutant SCN5A were increased, and the recovery time from caffeine is 
significantly prolonged in mutant cells. The presence of Ca2+ oscillations or 
“re-excitations” in N1325S HL-1 cells suggests that the abnormal Ca2+ handling may not 
stem from the higher content of SR Ca2+ content, but from a reduced ability to remove 
the cytosolic Ca2+ back to SR or out of the cells. Therefore, the prolonged reduction of 
cytosolic Ca2+ can cause another Ca2+ induce Ca2+ release (CICR) and give a second peak 
when adding caffeine. This result indicates the linkage between SCN5A mutation and 
abnormal Ca2+, the following series of experiments I had designed would further 
strengthen the correlation between these two. 
In order to investigate whether late sodium currents produced by N1325S mutation 
play a critical role in abnormal intracellular Ca2+ transient signals, I treated the cells with 
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late sodium current blockers, ranolazine and mexiletine. Following the treatment of 10 
µM of ranolazine or mexiletine, the recovery time from caffeine effects is significantly 
shortened with no change in amplitudes. This suggested that a reduction of excessive Na+ 
entry caused by late sodium currents will reduce the intracellular Na+ concentration and 
quicken the removal of cytosolic Ca2+ back to SR or out of the cells. The comparison of 
different SCN5A mutations on Ca2+ handling indicates that the SR Ca2+ content was not 
necessarily affected by late sodium currents because not only did N1325S, ΔKPQ and 
E1784K mutations increase the caffeine-induced peak Ca2+ response, but A1924T 
mutation also increased the peak Ca2+ response. A1924T mutation is a Brugada mutation 
causing negative shift of inactivation curve, INa increase and a larger action potential 
overshoot (Rook et al 1999). The overall impact on intracellular Na+ concentration is 
unknown. However, according to my results, the ability of removing extra cytosolic Ca2+ 
is correlated to the presence of late sodium currents produced by SCN5A mutations 
because only mutations that produce INa,L have significantly prolonged recovery time 
from caffeine. 
Since the first mutation in SCN5A related to cardiac arrhythmia was identified in 
1995 (Wang et al 1995b), various mutations in this gene have been found and associated 
with numerous arrhythmia syndromes, such as LQT3, Brugada syndrome, progressive 
cardiac conduction defect (PCCD), sick sinus node syndrome (SSS), atrial fibrillation 
(AF) and DCM. The molecular pathology of these mutations is still not fully understood. 
Ca2+ is a crucial element in all kinds of organisms, and it plays an important role in 
numerous biological functions. It is known that the intracellular free Ca2+ concentration 
(~10-7 M) is much lower than the extracellular Ca2+. This high Ca2+ gradient provides 
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abundant Ca2+ available to be imported into cells, where these Ca2+ ions can function as 
second messengers (Chin and Means 2000). Thus, the abnormal Ca2+ handling in some 
SCN5A mutations could play an important role in the development of cardiac arrhythmia.  
In conclusion, this study has established the correlation between gain-of-function 
sodium mutations and abnormal cytosolic Ca2+ handling in cardiac cells. I believe that the 
late sodium current is the cause for Ca2+ inhomogeneity caused by the N1325S mutation. 
I further showed that in the presence of late sodium current blocker, ranolazine or 
mexiletine, the prolonged recovery time from caffeine can be shortened. The advantage 
of this study over the isolated TG-NS adult myocytes is the introduction of HL-1 cells. 
HL-1 cells diminished the remodeling responses such as a higher apoptosis rate and 
up-regulations of Ca2+ handling proteins in aging TG-NS mouse hearts. The finding that 
abnormal intracellular Ca2+ transient signals are associated with gain-of-function LQTS 
SCN5A mutation may provide a molecular mechanism for the development of VT and 
DCM. 
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